Regulation of Interferon-Inducible 2’-5’-Oligoadenylate Synthetases by Adenovirus VA₁ RNA

By

Hui Meng

A thesis submitted to the Faculty of Graduate Studies of
The University of Manitoba
in partial fulfilment of the requirements for the degree of

MASTER OF SCIENCE

Department of Chemistry
University of Manitoba
Winnipeg, Manitoba

Copyright © 2012 by Hui Meng
Abstract

Viral double-stranded RNA is a key pathogen invasion signal recognized by the human innate immune system. All adenoviruses synthesize at least one highly structured RNA (VA₁) to suppress this antiviral response by attenuating the activity of antiviral proteins. Surprisingly, VA₁ RNA was previously shown to positively regulate the activity of one interferon-inducible antiviral protein, 2’-5’-oligoadenylate synthetases (OAS). The present thesis focuses on investigating the regulation of a human OAS1 isoform by VA₁ RNA and its derivatives. An *Escherichia coli* protein expression and purification system has been developed for OAS1 protein production. A combination of biochemical and biophysical approaches was employed to examine VA₁ RNA binding affinity, activation potential for OAS1 and OAS1:VA₁ RNA complex formation. Taken together, I have found that while full-length VA₁ does indeed activate OAS1 *in vitro*, a truncated version lacking the terminal stem has the opposite effect, and this is the physiologically important response.
Acknowledgments

It is a great pleasure to thank everyone who helped me during my research project and thesis writing. First, I would like to express my gratitude to my supervisor, Dr. Sean McKenna, for his knowledge, his encouragement, his understanding, and his great efforts to explain things simply and clearly. Without his professional guidance and valuable support, this thesis would not have been possible.

I would like to thank other members of my committee, Dr. Joe O’Neil, Dr. Mazdak Khajehpour, and Dr. Teresa De Kievit for their guidance and assistance during thesis writing. I also thank Dr. Mazdak Khajehpour for his insights into developing a quantitative enzyme assay for OAS1 activation and assistance with analysis.

I would also offer my thanks to all the former and current members in Dr. Sean McKenna’s Lab. Special thanks go to Soumya Deo for his technical assistance with OAS1 purification and activity assay. Advice given by Dr. Evan Booy and Edis Dzanaovic during my graduate program has been great help and greatly appreciated.

I must thank Dr. Jörg Stetefeld and Dr. John Sorensen research groups for providing access to their equipment and their technical assistance. I must acknowledge Dr. Lynda Donald for her expertise, suggestion and efforts in completion of mass spectrometry analysis. Appreciation also goes to Drs. Ken Standing and Werner Ens for providing access to mass spectrometry instruments, along with Victor Spicer and Dr. Vladimir Collado for their technical assistance.

I also express my gratitude to Natural Sciences and Engineering Research Council of Canada (NSERC) for financially supporting this work.

Finally, I would like to thank my family for all their love and endless support throughout years.
Dedication

I dedicate this thesis

to my husband, Feng Gao, for his support throughout years.

to my boys, Andy and Aiden, for bringing joy and happiness to my life.

to my parents for their love.
# Contents

Front Matter

Abstract ....................................................................................................................... ii
Acknowledgments .................................................................................................. iii
Dedication ............................................................................................................... iv
Contents ................................................................................................................... v
List of Tables ........................................................................................................ viii
List of Figures ........................................................................................................ ix
List of Copyrighted Material ................................................................................ xi
List of Abbreviations and Symbols ..................................................................... xii

## Chapter 1 Introduction .................................................................................. 1

1.1 Literature review ......................................................................................... 1

1.1.1 Interferon responses to viral dsRNA ......................................................... 1

1.1.1.1 Viral dsRNA sensing and IFN induction .............................................. 3

1.1.1.2 Inducible expression of ISGs .............................................................. 4

1.1.1.3 Regulation of IFN-inducible antiviral proteins by viral dsRNA ........ 5

1.1.2 OAS-RNaseL system .............................................................................. 6

1.1.2.1 RNA binding and OAS activation ...................................................... 8

1.1.2.2 Catalytic formation of 2’-5’-A ............................................................ 11

1.1.2.3 Activation of RNaseL and degradation of RNA by RNaseL .......... 11

1.1.3 Adenoviral virus-associated RNA I, VA₁ RNA .................................. 12

1.1.3.1 VA₁ RNA and PKR ........................................................................ 14
1.1.3.2 VA RNA and OAS ................................................................. 14
1.1.3.3 VA RNA and Dicer ............................................................. 15
1.1.4. Viral RNA sensing through 5’-end modifications ....................... 16
1.2 Thesis overview ............................................................................. 16

Chapter 2 Materials and Methods .......................................................... 19
2.1 Introduction ...................................................................................... 19
2.2 OAS1 purification ........................................................................... 20
  2.2.1 Overview .................................................................................... 20
  2.2.2 Procedures ................................................................................ 22
    2.2.2.1 Construction of pET30a(+) GNSHT-OAS1 expression vector .......... 22
    2.2.2.2 Expression and IPTG-induction of GNSHT-OAS1 fusion protein ...... 22
    2.2.2.3 Isolation of GNSHT-OAS1 fusion protein from cell lysate by affinity chromatography ................................................................. 23
    2.2.2.4 Cleavage of GNSHT-OAS1 fusion protein by TEV protease and purification via size exclusion chromatography .............................................. 24
    2.2.2.5 Confirmation of OAS1 by mass spectrometry ................................. 27
2.3 In vitro transcription and purification of VA RNA ................................ 27
  2.3.1 Overview .................................................................................... 27
  2.3.2 Procedures ................................................................................ 30
    2.3.2.1 Preparation of DNA templates and in vitro transcription................. 30
    2.3.2.2 Desalting of in vitro transcribed RNA ........................................ 31
    2.3.2.3 Purification of transcribed RNA using FPLC size exclusion chromatography ........................................................................................................... 31
## Chapter 2 OAS1 activity assay

### 2.4 Overview

### 2.4.2 Procedures

## Chapter 2.5 Electrophoretic mobility shift assays

## Chapter 2.6 Hydrodynamic radius determination

## Chapter 2.7 Mass spectrometry analysis of protein-RNA complexes

## Chapter 2.8 5’-end modification of RNA

### Chapter 3 Results

### 3.1 Introduction

### 3.2 Expression and purification of active OAS1 from *E. coli*

### 3.3 VA₁ lacking the terminal stem forms stable complexes with OAS1

### 3.4 Non-denaturing mass spectrometry of VA₁ΔTS-OAS1 complex

### 3.5 VA₁ lacking terminal stem is a poor activator of OAS1

### 3.6 RNA dissociation is observed upon OAS1 activation

### 3.7 Phosphorylation state at RNA 5’-end impacts OAS1 affinity and activation potential

### 3.8 Summary

### Chapter 4 Discussion and Conclusions

### 4.1 Discussion

### 4.2 Conclusions

### 4.3 Future studies

### References
List of Tables

Table 1  Estimated kinetic parameters for VA₁ derivatives and controls.......................... 54
List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Interferon responses to viral dsRNA</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>OAS enzyme reaction</td>
<td>7</td>
</tr>
<tr>
<td>3</td>
<td>OAS/RNaseL pathway</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>Domain organization in OAS enzymes</td>
<td>9</td>
</tr>
<tr>
<td>5</td>
<td>VA₁ RNA secondary structure</td>
<td>13</td>
</tr>
<tr>
<td>6</td>
<td>GNSHT-OAS1 coding region of pET30a(+)-GNSHT-OAS1tv2</td>
<td>21</td>
</tr>
<tr>
<td>7</td>
<td>Denaturing SDS-PAGE analysis of GNSHT-OAS1 fractions from Ni-NTA column</td>
<td>24</td>
</tr>
<tr>
<td>8</td>
<td>SDS-PAGE analysis of TEV cleavage of GNSHT-OAS1 fractions</td>
<td>25</td>
</tr>
<tr>
<td>9</td>
<td>Size exclusion chromatography (SEC) elution profile of OAS1 purification</td>
<td>26</td>
</tr>
<tr>
<td>10</td>
<td>In vitro RNA transcription and purification</td>
<td>29</td>
</tr>
<tr>
<td>11</td>
<td>OAS activity assay outline</td>
<td>33</td>
</tr>
<tr>
<td>12</td>
<td>Purification of active recombinant human OAS1</td>
<td>40</td>
</tr>
<tr>
<td>13</td>
<td>VA₁ lacking the terminal stem forms stable complexes with OAS1</td>
<td>43</td>
</tr>
<tr>
<td>14</td>
<td>Characterization of VA₁:OAS1 by DLS</td>
<td>44</td>
</tr>
<tr>
<td>15</td>
<td>Non-denaturing MS of OAS1:VA₁ TSΔ21 complexes</td>
<td>48</td>
</tr>
<tr>
<td>16</td>
<td>Effects of reducing agents on OAS1:VA₁ΔTS complex formation</td>
<td>50</td>
</tr>
<tr>
<td>17</td>
<td>Regulation of OAS1 activity by VA₁ RNA</td>
<td>53</td>
</tr>
<tr>
<td>18</td>
<td>RNA affinity decreases upon even modest OAS1 activation</td>
<td>56</td>
</tr>
<tr>
<td>19</td>
<td>5’-end phosphorylation impacts activity and affinity for OAS</td>
<td>58</td>
</tr>
</tbody>
</table>
Figure 20  VA$_1$ simultaneously antagonize both the RNAi machinery and the IFN-inducible antiviral proteins.
List of Copyrighted Material

Licensed content publisher: Elsevier

Licensed content publication: Journal of Molecular Biology

Licensed content title: Regulation of the interferon inducible 2’-5’-oligoadenylate synthetases by adenovirus VA I RNA.

Sections where the licensed materials can be found: 2.2.2.1, 2.2.2.2, 2.2.2.3, 2.2.2.4, 2.2.2.5, 2.3.2, 2.4.2, 2.5, 2.6, 2.7, 2.8, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 4.1, and 4.2.
List of Abbreviations and Symbols

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2’-5’-A</td>
<td>2’-5’-oligoadenylate</td>
</tr>
<tr>
<td>5’-OH</td>
<td>5’-hydroxyl</td>
</tr>
<tr>
<td>5’-P</td>
<td>5’-monophosphate</td>
</tr>
<tr>
<td>5’-PPP</td>
<td>5’-triphosphates</td>
</tr>
<tr>
<td>ARD</td>
<td>ankyrin repeat domain</td>
</tr>
<tr>
<td>AS</td>
<td>apical stem</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>BME</td>
<td>β-mercaptoethanol</td>
</tr>
<tr>
<td>C-F-K</td>
<td>cysteine-phenyalanine-lysine</td>
</tr>
<tr>
<td>CARD</td>
<td>caspase recruitment domain</td>
</tr>
<tr>
<td>CLA</td>
<td>chloramphenicol</td>
</tr>
<tr>
<td>CS</td>
<td>central stem</td>
</tr>
<tr>
<td>CV</td>
<td>column volume</td>
</tr>
<tr>
<td>DLS</td>
<td>dynamic light scattering</td>
</tr>
<tr>
<td>dsRBD</td>
<td>double-stranded RNA binding domain</td>
</tr>
<tr>
<td>dsRNA</td>
<td>double-stranded RNA</td>
</tr>
<tr>
<td>DTT</td>
<td>dithiothreitol</td>
</tr>
<tr>
<td>E. coli</td>
<td><em>Escherichia coli</em></td>
</tr>
<tr>
<td>EBER1</td>
<td>Epstein–Barr virus (EBV)-encoded small RNA I</td>
</tr>
<tr>
<td>EBV</td>
<td>Epstein–Barr virus</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>eIF2α</td>
<td>alpha subunit of eukaryotic initiation factors 2</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>EMSA</td>
<td>electrophoresis mobility shift assay</td>
</tr>
<tr>
<td>Exp 5</td>
<td>exportin 5</td>
</tr>
<tr>
<td>$f$</td>
<td>fraction of bound RNA</td>
</tr>
<tr>
<td>FPLC</td>
<td>fast-performance liquid chromatography</td>
</tr>
<tr>
<td>HEK293T</td>
<td>human embryonic kidney 293T cell</td>
</tr>
<tr>
<td>HIV-1</td>
<td>human immunodeficiency virus type I</td>
</tr>
<tr>
<td>HPLC</td>
<td>high performance liquid chromatography</td>
</tr>
<tr>
<td>HTLV-1</td>
<td>human T-cell leukemia virus type 1</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>IFNAR1/2</td>
<td>interferon-α/β receptor</td>
</tr>
<tr>
<td>IPTG</td>
<td>isopropyl-β-D-thio-galactopyranoside</td>
</tr>
<tr>
<td>IRF3</td>
<td>interferon regulatory factor 3</td>
</tr>
<tr>
<td>IRF9</td>
<td>interferon response factor 9</td>
</tr>
<tr>
<td>ISG</td>
<td>interferon-stimulated gene</td>
</tr>
<tr>
<td>ISGF3</td>
<td>interferon-stimulated gene factor 3</td>
</tr>
<tr>
<td>ISRE</td>
<td>interferon-stimulated response element</td>
</tr>
<tr>
<td>JAK</td>
<td>Janus kinase</td>
</tr>
<tr>
<td>KAN</td>
<td>kanamycin</td>
</tr>
<tr>
<td>$K_{app}$</td>
<td>apparent dissociation constant</td>
</tr>
<tr>
<td>$k_{cat}$</td>
<td>turnover number</td>
</tr>
<tr>
<td>$K_d$</td>
<td>dissociation constant</td>
</tr>
<tr>
<td>LB</td>
<td>Luria–Bertani</td>
</tr>
<tr>
<td>LGP2</td>
<td>laboratory of genetics and physiology2</td>
</tr>
<tr>
<td>MALDI</td>
<td>matrix-assisted laser desorption/ionization</td>
</tr>
<tr>
<td>MDA5</td>
<td>melanoma differentiation-associated gene 5</td>
</tr>
</tbody>
</table>
MS  mass spectrometry
NADPH  reduced nicotinamide adenine dinucleotide phosphate
NF-κB  nuclear factor kappa-light-chain-enhancer of activated B cells
Ni–NTA  nickle-nitrilotriacetic acid
NMR  nuclear magnetic resonance
NTP  nucleotide triphosphate
OAS  2’, 5’-oligoadenylate synthetase
PK  protein kinase-like domain
PKR  protein kinase RNA-dependent
poly I:C  polyinosinic-polycytidylic acid
PPi  pyrophosphate
PRR  pattern-recognition receptors
Pt  protein concentration at equilibrium
PTGS  post-transcriptional gene silencing
RH  hydrodynamic radii
RIG-I  retinoic acid-inducible gene-I
RISC  RNA-induced silencing complex
RLR  retinoic acid-inducible gene-I-like-receptor
RNAi  RNA interference
RNASE  ribonuclease domain
RNaseL  endoribonuclease L
RxRE  Rex-response element
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEC  size exclusion chromatography
siRNA  small-interference RNA
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAT</td>
<td>signal transducers and activators of transcription</td>
</tr>
<tr>
<td>TAR</td>
<td>trans-activating response region</td>
</tr>
<tr>
<td>TEV</td>
<td>tobacco etch virus</td>
</tr>
<tr>
<td>TIR</td>
<td>toll/interleukin-1 receptor</td>
</tr>
<tr>
<td>TLC</td>
<td>thin-layer chromatography</td>
</tr>
<tr>
<td>TLR3</td>
<td>toll-like-receptor 3</td>
</tr>
<tr>
<td>TRIF</td>
<td>TIR-domain-containing adapter-inducing interferon-β</td>
</tr>
<tr>
<td>TS</td>
<td>terminal stem</td>
</tr>
<tr>
<td>$V$</td>
<td>reaction velocity</td>
</tr>
<tr>
<td>$VA_I$</td>
<td>Adenoviral virus-associated RNA I</td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>maximum reaction velocity</td>
</tr>
</tbody>
</table>
Chapter 1

Introduction

1.1 Literature review

The human innate immune system is the first line of defense against viral invasion. In this system, interplay between viral components [including, viral double-stranded RNA (dsRNA)], type I interferons (IFN), and IFN-inducible antiviral proteins are crucial for antiviral responses. Recognition of viral dsRNA by cellular receptors triggers IFN production and IFN-related antiviral responses in virus-infected cells (1-3). In turn, viral dsRNA regulates the functions of IFN-inducible antiviral proteins (4, 5).

1.1.1 Interferon responses to viral dsRNA

dsRNA produced during the viral life cycle or directly from the viral genome function diversely and interact with key components in the human innate immune system (6-8) (Fig.1). Viral dsRNA are recognized by pattern-recognition receptors (PRR) to trigger a signalling cascade and ultimately to induce the expression of IFN in host cells (9-12). Type I IFNs stimulate host cells through a series of signal transduction pathways to express the interferon-stimulated genes (ISG) (8). The protein products encoded by these ISGs are responsible for a series of cellular antiviral responses to inhibit viral replication or enhance immune responses (1). Meanwhile, viral dsRNA also regulate the functions of these antiviral proteins (5).
Viral dsRNA is recognized by pattern-recognition receptors in host cells to trigger IFN induction signals (9, 12). The induced IFNs in turn simulate the expression of ISGs to enhance the innate immune antiviral activities to viral infection (8).
1.1.1.1 Viral dsRNA sensing and IFN induction

Viral dsRNA are recognized by PRRs and trigger a signalling cascade to induce the expression of IFNs and proinflammatory cytokines in the host cells. One well-characterized example of a PRR is the toll-like-receptor 3 (TLR3) (10). TLR3 recognizes viral dsRNA and is localized to either the cell membrane or the endosomal membrane (13). Once bound by dsRNA, TLR3 undergoes dimerization and recruits the toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF) protein via the TIR domain interaction in both TLR3 and TRIF. This interaction leads to the activation of interferon regulatory factor 3 (IRF3) resulting in the production of type I IFNs, IFN-α/β (14). Activated TLR3 can also activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a crucial transcription factor to regulate the gene expression in both innate and adaptive immune systems (11, 15, 16). Another example of a foreign dsRNA receptor is the retinoic acid-inducible gene-I-like-receptors (RLRs) (12). In this family, three members sharing the common features of dsRNA binding and helicase activity have been identified, and include retinoic acid-inducible gene-I (RIG-I), melanoma differentiation-associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) (17, 18). Similar to TLR3, RIG-I and MDA5 also activate signalling pathways to induce the expression of IRF3/7 and NF-κB, and ultimately leads to the induction of IFN-α/β and other cytokines (12). Both RIG-I and MDA5 contain two caspase recruitment domains (CARD), which are employed to interact with CARD-containing adaptor to trigger the downstream signalling (17). Unlike RIG-I and MDA5, LGP2 lacks N-terminal CARDs but has an ATPase domain that facilitates the dsRNA recognition by the first two enzymes (18). Together, viral dsRNA
are sensed by PPRs and trigger a signalling cascade to induce the production of IFN and other cytokines that in turn enhance the host immune responses to viral infections.

1.1.1.2 Inducible expression of ISGs

Upon induction by viral dsRNA signals, the induced type I IFNs are secreted into the intercellular space and bind to the cell-surface interferon-α/β receptors (IFNAR1/2) of surrounding cells resulting in the global expression of ISGs (19). The binding of IFNs to IFNAR1/2 trigger the activation of the Janus kinases (JAK) that in turn phosphorylate and activate the signal transducers and activators of transcription (STAT) (20, 21). STAT1, STAT2 and interferon response factor 9 (IRF9) assemble into a complex with interferon-stimulated gene factor 3 (ISGF3), which binds to the interferon-stimulated response element (ISRE) localized in the promoter sequences of ISGs (22, 23) (Fig.1).

The expressed protein products of these ISGs, also known as IFN-inducible antiviral proteins, are involved in many IFN-associated antiviral, antiproliferative and immunoregulatory responses (8, 24). Two key examples are IFN-inducible and dsRNA-binding proteins, 2′-5′-oligoadenylate synthetases (OAS) and protein kinase RNA-dependent (PKR) (25). As proven IFN-inducible antiviral proteins, both OAS and PKR suppress the protein translation required for virus assembly and replication, and are also involved in the downstream signalling transduction to amplify the cellular immune responses to viral infections (26, 27). OAS enzymes, upon interaction with dsRNA, become activated and polymerize ATP into 2′-5′-oligoadenylate (2′-5′-A) chains (28, 29). These oligoadenylate chains bind to and activate endoribonuclease L (RNaseL), which destroys RNA from the ribosome and virus itself, thereby restricting viral propagation (30, 31). The small RNA resulting from RNaseL cleavage can in turn act on
two pathogen recognition receptors, RIG-I and MDA5, to initiate IFN induction and amplify the antiviral responses (32, 33). Upon dsRNA binding, latent PKR undergoes dimerization and autophosphorylation to become active (34). The activated dimeric PKR phosphorylates the alpha subunit of eukaryotic initiation factors 2 (eIF2α) on its Ser51 site to inhibit protein translation in the virus-infected cells (34-36). In addition to eIF2α phosphorylation, PKR also interacts with other cellular proteins which function in RNA metabolism, such as RNA helicase A and human immunodeficiency virus type 1 (HIV-1) Tat (37, 38). Another key role of PKR is to regulate translation factors independent of phosphorylation. It has been demonstrated that PKR without kinase activity is capable of activating NF-κB (39).

1.1.1.3 Regulation of IFN-inducible antiviral proteins by viral dsRNA

Viral dsRNA also regulates the enzymatic functions of IFN-inducible antiviral proteins (5). In order to circumvent the IFN responses to viral infections, one strategy that viruses use is to generate highly-structured small RNA molecules to inhibit the activity of IFN-inducible antiviral proteins (3). The best-characterized example is the negative regulation of PKR by specifically transcribed viral dsRNA. Both Epstein-Barr virus (EBV)-encoded small RNA I (EBER₁) and adenoviral virus-associated RNA I (VA₁) have been shown to bind to PKR with similar affinity as dsRNA activators but prevent the self-association and autophosphorylation of the enzyme (40). In this way, the protein synthesis crucial for virus assembly can proceed unimpeded. In the case of OAS enzymes, however, it has been demonstrated that most characterized viral dsRNA serve as OAS activators, including EBER₁ (41), VA₁ (42), Rex-response element (RxRE) of human T-cell leukemia virus type 1 (HTLV-1) (43), and trans-activating response region
(TAR) of HIV-1 (44). The basis for the opposite roles played by viral dsRNA (e.g. EBER<sub>1</sub> and VA<sub>1</sub>) with OAS and PKR remains poorly understood, which was the main source for my research project. In addition to regulating OAS, it has been shown that viral RNA can inhibit the OAS downstream effector RNaseL (45). An RNA structure from a poliovirus open reading frame inhibits the RNA cleavage ability of RNaseL during the early stages of infection (46).

Taken together, viral RNAs generated during virus replication cycles play diverse roles in the host IFN antiviral system. These RNAs serve as viral stress signals to trigger the induction of type I IFNs, as regulatory cofactors for IFN-inducible antiviral proteins and also as the acting targets of host antiviral activities. These functions all involve the interactions between host proteins and viral RNAs. Thus examination of such interactions would clarify our understanding of how the host defence system detects the viral invasion and aid finding potential RNA therapeutic agents for either viral or autoimmune diseases. In my thesis, I sought to understand the regulation of OAS activity by adenoviral VA<sub>1</sub> RNA. In the following sections, key details about OAS-RNaseL system and VA<sub>1</sub> RNA will be reviewed to place my results in the proper context.

1.1.2 OAS-RNaseL system

The OAS-RNaseL system is a key player in degradation of viral and cellular RNA in virus-infected cells. OAS enzymes were discovered more than 35 years ago, resulting from the demonstration that protein synthesis is blocked by dsRNA from IFN-stimulated cells (47, 48). These enzymes are unique in that they catalyze the formation of 2’-5’-phosphodiester bonds instead of 3’-5’-phosphodiester ones (Fig.2). Upon induction
by IFN and binding to dsRNA, OAS enzymes polymerize adenosine triphosphate (ATP) into 2′-5′-oligoadenylates (2′-5′-A), which are the only known activators for the antiviral endoribonuclease, RNaseL (Fig. 3). In turn, the activated RNaseL degrades both viral and cellular RNA to inhibit protein synthesis and block viral infection (30, 49). The key mechanistic steps involved in this pathway are: (i) RNA binding and activation of OAS, (ii) catalytic formation of 2′-5′-A, (iii) activation of latent RNaseL, and (iv) degradation of RNA by RNaseL. The details of each step will be discussed below.

**Figure 2** OAS enzyme reaction

OAS enzymes catalyze the unique 2′-5′-A chain formation instead of 3′-5′-A chains (67).
1.1.2.1 RNA binding and OAS activation

Generally, human OAS enzymes are classified into three functional forms based on the numbers of the core OAS units. OAS1, OAS2 and OAS3 contain one, two and three OAS units, respectively (50, 51) (Fig.4). In OAS1, the core OAS unit includes the first 346 N-terminal amino acids (52). In addition to these three forms, OASL (OAS like protein) has one OAS unit and two ubiquitin-like domains but is devoid of the OAS enzymatic activity (53, 54).
OAS enzymes are expressed at low constitutive levels in human cells. Once induced by type I IFNs, inactive OAS accumulates in the cytoplasm. Upon binding to and activation by viral dsRNA, inactive OAS1 and OAS2 enzymes are proposed to convert into the active forms via oligomerization (55). It has been found that the mutation of C-F-K (cysteine-phenyalanine-lysine) amino acid residues located in the core OAS unit of OAS1 and OAS2 significantly affected the tetramerization and dimerization of OAS1 and OAS2, respectively (56). There is no C-F-K motif in either OAS3 or OASL, and therefore their active forms are proposed to remain monomeric (56). However, monomeric and fully active OAS1 has been observed by two groups (57, 58).

OAS1, OAS2 and OAS3 contain one, two and three OAS units, respectively (50, 51). OASL (OAS like protein) has one N-terminal OAS unit and two C-terminal ubiquitin-like domains (54).
Thus, the importance of self-association of OAS enzymes for enzymatic activation needs further investigation.

OAS enzymes are a highly conserved family but share no considerable sequence homology to other known dsRNA-binding proteins or to any known dsRNA-binding motif. According to the high-resolution crystal structure of porcine OAS1, a positively charged groove on the back face of the bilobal structure, roughly parallel to the active site, is the putative dsRNA-binding site (59). Hartmann and colleagues observed that the binding affinities of different aptamers to OAS1 do not couple with their activation abilities, which supports a two-step process for OAS activation (60). First, dsRNA binds to the OAS enzyme in a relatively non-specific way followed by a conformation change to OAS enzyme structure. The structural rearrangement of OAS enzyme is hypothesized to enable the easy access of substrate to the active site. The activation of OAS enzymes depends on a number of dsRNA properties including the length (e.g. >15 bp ds region), sequence composition, nucleotide modification, secondary structure and deviations from perfect RNA duplex (60-64). Polyinosinic-polycytidylic acid (poly I:C) is a synthetic analog of dsRNA (average molecular weight ~ 200 KDa) and conventionally used as an activator for OAS enzymes. As a immunostimulant, polyI:C is a good tool for immunology research as it will induce the IFN cascade. However, in order to understand the interaction between OAS enzymes and their natural dsRNA activators, polyI:C is inappropriate and actual viral dsRNA need to be examined.
1.1.2.2 Catalytic formation of 2’-5’-A

The enzymatic activity to form 2’-5’-linked oligonucleotides instead of 3’-5’-linked oligonucleotides is a unique feature of OAS enzymes. The active site of OAS enzymes is localized at the interface between N- and C- terminal domains in the core OAS unit (59). The N-terminal domain of each OAS unit contains the three aspartic residues that are thought to coordinate two Mg$^{2+}$ ions required for catalysis, typical of the nucleotidyl transferase family. The helical turn sequence containing a Gly-Ser motif also exists in the N-terminal domain of the OAS unit that is thought to interact with the donor ATP via a hydrogen bond with serine (29, 59, 65). However, the mechanism of interaction with the acceptor ATP and how the 2’-hydroxyl reacts with the donor α-phosphate moiety remains unclear. According to structural and mutagenesis analysis, it is believed that the 2’ specificity of the OAS enzyme depends on the orientation of the acceptor ATP to enable the 2’-hydroxyl to react (59, 65).

The types of 2’-5’-A chain synthesis vary among OAS enzymes. OAS1 and OAS2 are able to synthesize trimer and tetramer 2’-5’-A species and even longer under the optimized condition \textit{in vitro}, whereas OAS3 primarily catalyzes the formation of dimeric 2’-5’-A which is not an efficient activator of RNaseL (66, 67). It is therefore hypothesized that OAS3 may function in other cellular processes unrelated to RNaseL-mediated RNA degradation.

1.1.2.3 Activation of RNaseL and degradation of RNA by RNaseL

The only established biological function of 2’-5’-A is to activate RNaseL. The latent RNaseL is widely expressed in most human tissues as an inactive monomer (68).
The main domains of RNaseL are ankyrin repeat domain (ARD), protein kinase-like domain (PK) and ribonuclease domain (RNASE) (69). \(2'\text{--}5'\text{-A}\) with qualified length (at least trimer) binds to the ARD domain, which triggers the homodimerization of latent RNaseL monomer (49). The active RNaseL cleaves ssRNA via its RNASE domain (69, 70). Active RNaseL degrades the viral genomic RNA and acts on the viral mRNA to block viral protein synthesis. The RNaseL substrates come not only from the viral genome themselves, but also from the host cell (68). RNaseL also degrades host cellular RNAs including mRNA and rRNA in such a way to destroy the host cell machinery that is required for virus replication and eventually decrease the viability of virus. In turn, small RNA products from RNaseL cleavage can induce IFN-\(\beta\) to amplify the IFN immune responses (49). Evidence has also shown that RNaseL may induce apoptosis in virus-infected cells to prevent virus from spreading to the healthy cells (71).

### 1.1.3 Adenoviral virus-associated RNA I, VA\(_1\) RNA

The focus of my thesis is to investigate the interaction between a specific viral RNA, VA\(_1\) from adenovirus and OAS1 enzyme. Adenoviruses are nonenveloped viruses that are composed of a linear double-stranded DNA genome and a capsid. These viruses are mainly responsible for upper respiratory infections, especially in children. Outcomes associated with adenovirus infection vary from common cold to pneumonia, croup and bronchitis (72). The genomes of most adenovirus serotypes encodes two non-coding small virus-associated RNAs, VA\(_1\) and VA\(_{11}\) and are produced in the infected host cells by using host transcription machinery (73). VA\(_1\) RNA is the major species, which reaches \(~10^8\) copies (\(\mu\)M concentration) during late stages of viral replication, whereas
VA_{II} RNA is the minor species (maximum ~10^6 copies) (73, 74). They each contain approximately 160 nucleotides and fold into secondary structures containing primarily dsRNA stem-loops (Fig.5) (74). Since VA_{I} RNA is the major species, most studies have been focused on this molecule. VA_{I} RNA is transcribed in the nucleus by host RNA polymerase III, and then transported by exportin 5 (Exp 5) to the cytoplasm in the adenovirus-infected cell (75). The secondary structure of VA_{I} RNA features three major domains: the terminal stem (TS), the central stem (CS), and the apical stem (AS) (Fig.5). TS and AS domains are imperfectly base-paired, and CS is a structurally complex domain (76).

**Figure 5** VA_{I} RNA secondary structure

Secondary structures of (A) adenovirus VA_{I} RNA (40) with the Dicer cleavage site indicated by an arrow, (B) the terminal stem truncation (VA_{I}TS) (85), (C) the central stem loop alone (VA_{I}CS), and (D) the apical stem-loop alone (VA_{I}AS).
VA1 RNA is required for viral mRNA translation during late stages of infection, and plays key role during viral replication by directly interacting with innate immunity protein partners in virus-infected cells (73, 75). Studies have shown that VA1 RNA induces IFN production via the RIG-I signalling pathway, blocks the activation of PKR to allow the viral and host protein synthesis to proceed, serves as the substrate for Dicer to generate small RNAs acting as a small-interference RNA (siRNA) and acts on OAS1 enzyme as an RNA activator (40, 42, 77, 78). Details on each of these key interactions with innate immune proteins are discussed below.

1.1.3.1 VA1 RNA and PKR

VA1 RNA acts as a competitive inhibitor to block the activation of PKR, thus preventing dsRNA activators from binding to this antiviral protein (79, 80). Binding of VA1 RNA to PKR is achieved via the AS domain binding to the double-stranded RNA binding domains (dsRBD) of PKR, whereas inhibition also requires the central domain of VA1 RNA (81). VA1 RNA has a similar affinity for PKR as other viral dsRNA activators, and this binding prevents the required self-association of PKR for activation (40). Without self-association, PKR autophosphorylation is attenuated and the kinase activity is also inhibited so that protein synthesis proceeds at normal level in virus-infected cells (40).

1.1.3.2 VA1 RNA and OAS

A single study has demonstrated that full-length VA1 RNA activates the murine OAS enzyme, which is paradoxical given the inhibitory role that VA1 RNA plays with respect to PKR (42, 80). The main observation of this study is that VA1 RNA binds to
and activates the murine OAS enzyme that was expressed recombinantly in bacterial cells. They also showed that the long duplex regions in the AS and TS domains were crucial for OAS activation. When the imperfectly base-paired regions were converted into perfect base pairs, the OAS activation potential was dramatically increased. Meanwhile, disruption of the CS domain led to a reduction in OAS activation but did not affect binding. However, the authors did not define the specific VA₁ RNA domains responsible for OAS binding and activation.

1.1.3.3 VA₁ RNA and Dicer

RNA interference (RNAi) is a naturally occurring post-transcriptional gene silencing (PTGS) process mediated by dsRNA eventually leading to the degradation of target homologous mRNA (82). Dicer is a key dsRNA-specific endoribonuclease at the heart of the RNAi pathway (83). Longer initiating dsRNA is processed by Dicer into siRNA approximately 22 nucleotides long, which is unwound and incorporated into an RNA-induced silencing complex (RISC) to target mRNA matching the source RNA for degradation (6, 83). Recent studies have shown that VA₁ RNA serves as a substrate for Dicer (78, 84). Both in vitro and in vivo studies have shown that VA₁ RNA is processed by Dicer between CS and TS domains to form one long and one short dsRNA (Fig.5) (84, 85). The long dsRNA binds to and inactivates PKR to enable continued protein synthesis in virus-infected cells (85). One of the strands from the processed short dsRNA (equivalent to the TS domain) is incorporated into an active RNA-induced silencing complex (78, 84, 86). Therefore, the current data points to the enticing possibility that a single VA₁ molecule may simultaneously antagonize both the RNA interference machinery (via a processed terminal stem) and the interferon response (via the remaining
apical and central stems). It also suggests that VA₁ RNA may exist as three different forms *in vivo*, full-length VA₁, AS-CS domain and TS domain alone.

**1.1.4. Viral RNA sensing through 5’- end modifications**

A final feature to be introduced is the concept of how a host cell differentiates self- from foreign dsRNA. The presence of a 5’-triphosphate group is a signature of viral RNA that is distinct from the mature host RNA present in the cytoplasm (87-89). Initially, host mRNAs are transcribed with a 5’-triphosphate group in the nucleus, but are rapidly processed through post-transcriptional modifications, including cleavage, 7-methylguanosine capping, polyadenosine tail addition and base modification, and then transported into the cytoplasm as a mature mRNA (90). Viral dsRNA sensors (for instance, PKR and RIG-I) that exist in the cytoplasm can distinguish viral from self RNA through the recognition of 5’-triphosphate group on viral RNAs. It has been reported that PKR can be activated by short stem-loop RNA in a 5’-triphosphate-dependent fashion (91). RIG-I, as an innate immune sensing helicase, has also been demonstrated to recognize RNA stem-loops through a 5’-triphosphate group (87). The role of 5’-triphosphate group on viral RNA has not been investigated for OAS enzymes.

**1.2 Thesis overview**

2’-5’-OAS and PKR are interferon-inducible, dsRNA binding, antiviral enzymes (25). The mechanism of interactions between PKR and its dsRNA-binding partners has been reasonably well characterized, as several viral dsRNAs have been investigated (38, 40, 43, 44, 92, 93). Due to the difficulty in OAS enzyme purification and the low affinity
binding with its dsRNA cofactors, the molecular basis of OAS-dsRNA interactions remains unclear. One study has shown that human adenoviral virus-associated type I RNA, VA₁ RNA binds to and activates OAS enzyme in vitro (42), whereas studies have demonstrated that VA₁ RNA binds to and inactivates PKR (40, 85). The paradoxical roles played by VA₁ RNA with respect to OAS and PKR regulation forms the basis for this thesis. The secondary structure of VA₁ RNA features three major domains: the terminal stem (TS), the central stem (CS), and the apical stem (AS) (75). Recent investigation suggested that VA₁ RNA is processed by Dicer into two species: a TS-lacking VA₁ RNA and small RNA from TS in vivo (84). In light of this discovery that Dicer efficiently truncates VA₁, we decided to investigate the regulation of the specific OAS1 isoform (p42) by both the full length VA₁ and a series of truncated molecules, including one that corresponds to the Dicer-processed version lacking the terminal stem (VA₁ΔTS). No studies to date have shown the effects of VA₁ΔTS on OAS enzymes. The role of individual VA₁ RNA stem-loops (e.g. AS and CS) during interaction with OAS also remains unclear. Thus, one goal of my research project is to characterize the particular regions of VA₁ RNA that contribute to the activation of OAS and determine the regulatory effect of VA₁ RNA on OAS activity by biochemical and biophysical approaches. The other goal of my project is to identify the structural characteristics of OAS-VA₁ RNA complex by structural biology methods.

In order to achieve the goals mentioned above, an Escherichia coli (E. coli) protein expression and purification system has been developed and optimized for recombinant human OAS1 p42 isoform production. Full-length VA₁ RNA and its truncated forms, including VA₁-AS, VA₁-CS, VA₁ ΔTS (a mimic of Dicer-processed VA₁
RNA) RNAs were transcribed by T7 polymerase and isolated through an extensive purification procedure. A rapid and simple colorimetric method was developed to determine OAS activation by VA₁ RNA and its truncated forms by detecting pyrophosphate (PPI) released by 2’-5’-A formation from ATP. Activation assays demonstrated the ability of different RNAs to stimulate 2’-5’-A chain formations; full-length VA₁ RNA activates OAS1 whereas VA₁ ΔTS does not. Electrophoretic mobility shift assays (EMSA) were employed to determine the binding affinity of each RNA for OAS1. Only VA₁ ΔTS was capable of forming detectable complexes with OAS enzyme. EMSA results also suggested that VA₁ ΔTS forms two higher molecular weight complexes with OAS. Further, a novel non-denaturing mass spectrometry (MS) approach was used to characterize VA₁ΔTS-OAS complexes. VA₁ΔTS-OAS complexes were identified at 1:1 and 1:2 ratios by MS under non-denaturing conditions. Additionally, the importance of the RNA 5’-end phosphorylation state to its ability to regulate OAS1 activity has been investigated.

Taken together, using a combination of biochemical approaches, we characterize both the RNA-protein complex formation and activation/inhibition potential of full length VA₁ and a series of truncated molecules. Our conclusion is that while full-length VA₁ does indeed activate OAS1 in vitro, the Dicer-truncated molecule lacking the terminal stem has the opposite effect.
Chapter 2

Materials and Methods

2.1 Introduction

Our main goal was to characterize the ability of VA₁ RNA to regulate a key IFN-inducible member of the innate immune response, OAS1. A necessary precursor to these studies was to prepare and purify OAS1 enzyme and VA₁ RNA with high yield and purity to perform biochemical and biophysical characterizations. For OAS1 purification, an *E. coli* expression and purification procedure was developed and optimized. Once optimized, OAS1 enzyme could be expressed and purified within one week at a reasonable yield (1.5 to 2.0 mg/L cell culture). Five human OAS1 isoforms (p42, p44, p46, p48 and p52) have been identified that are generated through the alternative splicing of the same gene (52, 94). These OAS1 isoforms have the identical first 346-amino acids and differ in the C-terminal domain. Since OAS1 p42 is the smallest and simplest (18 amino acids in the C-terminus), we decided to start with this specific isoform. For RNA purification, an established plasmid-based *in vitro* transcription procedure was employed to synthesize VA₁ RNA and its truncated derivatives. Pure RNA species could be generated in one week at a high yield for biochemical and structural studies. Further, a colorimetric assay was developed for OAS enzymes to eliminate the need for radioactive ATP. To examine VA₁ RNA-OAS1 complexes, EMSA, dynamic light scattering (DLS), and MS were used. Finally, the importance of RNA 5’-end phosphorylation state to its
ability to regulate OAS1 activity was investigated by 5’-end dephosphorylation of *in vitro* transcribed RNA. The details of each procedure used will be discussed in the following sections (2.2-2.8).

### 2.2 OAS1 purification

#### 2.2.1 Overview

It has been over 35 years since OAS enzymes were discovered as IFN-inducible antiviral proteins (47, 48). In the early 1980s, OAS enzymes were mainly purified from IFN-treated cell cultures by employing ammonium sulfate precipitation and polyinosinic-polycytidylic-cellulose (95, 96). With the development of recombinant protein expression systems, OAS enzymes have been expressed in different types of cells, including bacterial and insect cells (97-99). A baculovirus-insect cell system has been employed to express both OAS1 and OAS2 enzymes (98, 100). Compared to the *E. coli* expression system, the baculovirus-insect cell system has two main drawbacks: high-cost cell-culture media and long cell-growth cycles. Unfortunately, it has been shown that the yield of OAS enzymes expressed in *E. coli* cells is low due to inclusion body formation (99, 101). Since *E. coli* expression systems have the advantage of low cost, fast cell-growth rate, simplicity and high expression level, we decided to express a specific human OAS1 (isoform p42) in BL21-CodonPlus(DE3)-RIL *E. coli* cells. The specific BL21-CodonPlus(DE3)-RIL *E. coli* cells contain extra tRNA genes rarely found in *E. coli* cells but used by human cells, which can reduce the codon bias effect on target protein expression (102). In order to increase the solubility of the target protein, the human *oas1tv2* gene was inserted into a non-commercial pET30a(+)GNSHT vector.
This expression vector codes for a fusion protein containing, from N-terminus to C-terminus, the highly soluble GB1 domain (G) from protein G of group G Streptococcus, the highly soluble NusA protein (N) from E. coli, a streptavidin tag (S), an 8×His tag (H), a TEV protease site (tobacco etch virus, T), and OAS1tv2 (encoding the OAS1 p42 isoform) (Fig.6). GB1 domain and NusA proteins increase the solubility of overexpressed protein in solution (103). The 8×His tag is used to separate the GNSHT-OAS1 fusion protein from the total protein in the cell lysate (104). The TEV protease recognition site (E-N-L-Y-F-Q-S) is employed to cleave the GNSHT tag off OAS1 to generate the tag-free target protein (105). After TEV cleavage, OAS1 itself still remains soluble in solution. The final yield of OAS1 enzyme is about 1.5-2.0 mg per liter cell culture. Thus, by employing the pET30a(+)·GNSHT vector and BL21-CodonPlus (DE3)-RIL E. coli cells, the OAS1 enzyme was expressed and purified at a reasonable yield for our studies.

**Figure 6**  GNSHT-OAS1 coding region of pET30a(+)·GNSHT-OAS1tv2

From N-terminus to C-terminus, the highly soluble protein G domain B1 (GB1), the highly soluble NusA protein (NusA), a streptavidin tag (Strep), an 8×His tag (8×His), a TEV protease site (TEV), and OAS1tv2 (OAS1).
2.2.2 Procedures

2.2.2.1 Construction of pET30a(+)–GNSHT-OAS1 expression vector

The original oas1tv2 gene on the plasmid pOTB7 (Open Biosystems) was used as template for PCR amplification using the following primers: 5’OAS1–GNSHT (GCGCGCGCGTCGACATGATGGATCTCAGAAATACCCCAGCCAAATCTCTGGACAAGTTCATTGAAGACTATCTCTTTGCC) and 3’OAS1–GNSHT (GCGCGCGCGGCCGCTCAAGCTTCATGGAGAGGGGCAGGGATGAATGGCAGGGAGGAAGCAGG GAGGAAGCAGG). The resulting PCR product was ligated into a modified pET30a(+) vector (pET30a(+)–GNSHT) (supplied by Dr. Tinghe Wu, Stanford University) in the multiple cloning site to generate the pET30a(+)–GNSHT-OAS1tv2 expression vector shown as in Fig. 6. All restriction enzymes and buffers were purchased from NEB (New England Biolabs), and the ligation was performed following the Quick Ligation™ Kit protocol from NEB.

2.2.2.2 Expression and IPTG-induction of GNSHT-OAS1 fusion protein

The overexpression of GNSHT-OAS1 enzyme in E. coli cells followed a standard protein expression procedure. The pET30a(+)–GNSHT-OAS1tv2 construct was transformed into BL21-CodonPlus(DE3)-RIL competent E. coli cells. A single freshly transformed colony from an Luria–Bertani (LB) agar plate containing 20 μg/ml chloramphenicol (CLA) and 30 μg/ml kanamycin (KAN) was inoculated into 10 ml of LB liquid broth containing the same antibiotics. The concentrations of antibiotic stocks are 20 mg/ml (CLA in methanol) and 30 mg/ml (KAN in water). After growing at 37°C for 12-14 h, the 10 ml starter culture was transferred into 1 L LB liquid broth.
supplemented with the same antibiotics and grown at 37°C. When the OD$_{600}$ value reached 0.6-0.8, the cell culture was cooled on ice for 15 min, and then the inducing reagent, isopropyl-β-D-thio-galactopyranoside (IPTG), was added to a final concentration of 1 mM. During the cooling period, the incubator was cooled down to 22°C. Then the cell culture was grown at 22°C with shaking at 200 rpm for an additional 16 h to express the protein.

2.2.2.3 **Isolation of GNSHT-OAS1 fusion protein from cell lysate by affinity chromatography**

The induced bacterial cells were collected by centrifugation at 6,000 × g for 15 min at 4°C, and then the cell pellets were resuspended in cell lysis buffer (50 mM Tris-HCl, 1 M NaCl, 1 mM imidazole, 5% glycerol and 1 mM DTT, pH 7.5). The resuspended cells were disrupted by sonication on ice (20 s pulses at 30 s intervals for 10 cycles) followed by centrifugation at 35,000 × g for 40 min at 4°C. The cell pellets were discarded and the supernatant was transferred into dialysis tubing with a 10 KDa cut-off and dialyzed in wash buffer (50 mM Tris-HCl, 1 M NaCl, 10 mM imidazole, 5% glycerol and 1 mM DTT, pH 7.5) to adjust the pH of lysate to 7.5. The cell lysate was then loaded onto a Ni–NTA (nickel-nitrilotriacetic acid) gravity-flow column [10 ml column volume (CV), QiaGen Inc.] equilibrated with wash buffer. The Ni-NTA column is conventionally used to purify His-tagged protein. The flow-through was collected and reloaded onto the same column. After loading cell lysate, the column was washed with 25×CV of wash buffer to remove the non-specifically bound proteins. Then, immobilized protein was eluted into 10-ml fractions by addition of 10×CV of elution buffer (50 mM Tris-HCl, 300 mM NaCl, 100 mM imidazole, 5% glycerol and 1 mM DTT, pH 7.5). Fractions were checked by
8% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) running in 1× SDS-PAGE running buffer. GNSHT-OAS1 protein is mainly found in the first three fractions (Fig. 7).

**Figure 7** Denaturing SDS-PAGE analysis of GNSHT-OAS1 fractions from Ni-NTA column

From left to right, lanes correspond to molecular weight markers, eluted fractions 1 to 6 from Ni-NTA column. The 8% SDS-PAGE was run at 150 V and stained with Coomassie blue. F indicates the fraction eluted from Ni-NTA column. The migration of fusion protein (GNSHT-OAS1) and the affinity tag (GNSHT) are indicated.

**2.2.2.4 Cleavage of GNSHT-OAS1 fusion protein by TEV protease and purification via size exclusion chromatography**

The eluate containing the GNSHT-OAS1 fusion protein from the Ni-NTA column was pooled and dialyzed against TEV protease working buffer (50 mM Tris-HCl,
100 mM NaCl, 1 mM EDTA, 5% glycerol and 1 mM DTT, pH 7.5). Then, the GNSHT-OAS1 fusion protein was incubated with TEV protease made in-house at room temperature for 16 h and the reaction was carried out in the dark. The next day, the TEV protease-treated fusion protein was checked by 8% SDS-PAGE to confirm the cleavage efficiency (Fig.8).

**Figure 8** SDS-PAGE analysis of TEV cleavage of GNSHT-OAS1 fractions

![SDS-PAGE analysis](image)

From left to right, lanes correspond to fraction from Ni-NTA column, cleavage of the fusion protein with TEV protease, and molecular weight markers (same as shown in Fig.7). The 8% SDS-PAGE was run at 150 V and stained with Coomassie blue. The migration of fusion protein (GNSHT-OAS1), the affinity tag (GNSHT), and OAS1 protein are indicated. TEV cleavage reactions were performed in triplicates under the same conditions.
Next, the cleaved protein was isolated via size exclusion chromatography (SEC) on HiLoad Superdex 200 (26/60, GE Healthcare) performed at 3 ml/min with storage buffer (50 mM Tris-HCl, 100 mM NaCl, and 1 mM DTT, pH 7.5). The SEC elution profile of OAS1 is shown in Fig.9.

**Figure 9**  Size exclusion chromatography (SEC) elution profile of OAS1 purification

SEC purification of OAS1 was performed on HiLoad Superdex 200 26/60 at 3 ml/min and eluted with storage buffer (50 mM Tris-HCl, 100 mM NaCl, and 1 mM DTT, pH 7.5). UV readings were recorded at both 280 and 260 nm. Fractions from each peak were checked by 8% SDS-PAGE as previously described, and partial SDS-PAGE results are shown in the inset.
2.2.2.5 Confirmation of OAS1 by mass spectrometry

Purified OAS1 protein was excised from SDS-PAGE gels. In-gel reduction, alkylation and destaining were performed as described previously (106). Peptide mixture (0.5 μl) was mixed with DHB matrix solution (0.5 μL, saturated 2,5-dihydroxybenzoic acid in 2% formic acid, 25% acetonitrile) on a MALDI target. Spectra were obtained on a MALDI time-of-flight instrument (107). The accumulated peak list was sent to MASCOT (www.matrixscience.com), and putative OAS1 peptides were then analyzed by tandem mass spectrometry on the same instrument (108).

2.3 In vitro transcription and purification of VA1 RNA

2.3.1 Overview

For biochemical and structural studies of RNA-protein interactions, milligrams of high quality RNA are required. In general, two RNA synthesis methods are used conventionally: chemical synthesis and in vitro transcription by bacteriophage T7 RNA polymerase. RNA chemical synthesis is expensive and is not suitable for synthesizing long RNA (>50 nt) (109). For longer RNAs (>50 nt), in vitro transcription by T7 polymerase is employed (110). In this method, RNAs are transcribed from linearized DNA templates by T7 polymerase under the optimized conditions, including Mg^{2+} and nucleotide triphosphate (NTP) concentrations (111). T7 polymerase is readily expressed and purified from E. coli cells in house and stored in a suitable buffer at -20°C for weeks. For transcription of longer RNAs, the DNA templates can be synthesized biochemically as linearized plasmids. After transcription by T7 polymerase, RNAs are not fully pure to be used for further biochemical or structural experiments. In the initial transcribed RNA
samples, there are several impurities present: abortive transcripts, premature termination products, hydrolyzed RNA products, DNA templates, excessive NTPs and T7 polymerase. In order to purify RNAs from these impurities, preparative gel electrophoresis has traditionally been used (112). Two major drawbacks limit the application of these methods in the large-scale production of RNAs. One is the limiting sample loading volume in the gel. The other is the gel components associated with RNA representing further impurities (111). Fast-performance liquid chromatography (FPLC) has been used as a standard method to purify large amounts of macro-biomolecules, such as proteins and nucleic acids (113). By FPLC, the RNA of interest is separated from other impurities based on their hydrodynamic size. RNA transcription from a DNA plasmid together with FPLC, therefore, provides a fast, large-scale method to prepare longer RNA materials for structural biology study. In my thesis work, a DNA template-based in vitro RNA transcription and purification procedure was employed (114). This procedure includes the following steps: DNA template preparation, in vitro transcription, phenol/chloroform extraction, desalting of in vitro transcribed RNA, FPLC size-exclusion chromatography, RNA concentration and quality control assay, and storage (114, 115) (Fig.10). Specifics of each step will be outlined in the following section (2.3.2).
Figure 10  *In vitro* RNA transcription and purification

Schematic outline of *in vitro* RNA transcription and purification steps. Details of each step are described in sections (2.3.2).
2.3.2 Procedures

2.3.2.1 Preparation of DNA templates and *in vitro* transcription

A large-scale and non-denaturing approach was employed to generate VA$_1$ RNA and its truncated derivatives, VA$_1$ΔTS, VA$_1$-AS and VA$_1$-CS *in vitro*. Their sequences and secondary structures are illustrated in Fig.5. Briefly, the DNA templates used for *in vitro* transcription were purified following the Zyppy™ Plasmid Maxiprep protocol (ZYMO RESEARCH), and linearized by incubating with BsaI or BstI at 37°C overnight. The linearized DNA templates were precipitated with 3 M sodium acetate and a four-fold excess of cold ethanol, and pelleted by centrifugation. The DNA pellet was dissolved in HPLC-grade water to a final concentration of 500 µg/ml. The small-scale trial transcriptions were required to optimize reaction conditions, especially the amount of T7 RNA polymerase and the concentrations of MgCl$_2$. A typical small-scale reaction contained the following: 1x transcription buffer (40 mM Tris-HCl (pH8.1), 1 mM spermidine, 0.001% (wt/vol) Triton X-100 and 10 mM DTT in HPLC water), 8 mM NTPs (ATP, GTP, CTP, UTP, 2 mM each), 2.5 µg linearized DNA template, varying concentrations of MgCl$_2$ (ranging between 5 and 20 mM in 5 mM increments), and 0.5, 1.0 or 2.0 µl of T7 RNA polymerase. The trial reactions were incubated at 37°C for 1-2 h, and 10-µl aliquots were assayed by denaturing TBE-PAGE. For denaturing TBE-PAGE, the gel mixture contained 8 M Urea to denature secondary RNA structures. RNA samples were mixed with denaturing loading buffer [0.02% bromophenol blue, 0.01% xylene cyanol FF, 10% glycerol, 8 M Urea in 1×TBE (89 mM Tris, 89 mM Boric acid, 2 mM EDTA, pH at 25°C: 8.0)] and preheated at 95°C for 5 min. After loading, the gels
were run at 100 V for 1-2 hr in 1×TBE, stained in 0.1% toluidine blue solution for 5 min, and then destained in water to visualize the RNA bands. After optimizing the reaction conditions, the small-scale transcriptions were scaled up to the desired size, and the large-scale transcriptions were incubated for 3-4 h at 37°C. Following removal of the pyrophosphate precipitate by centrifugation, the transcription reaction was quenched by adding excess EDTA to a final concentration of 50 mM to chelate the remaining Mg\(^{2+}\). An equal volume of phenol/chloroform (1:1) was added to the quenched reaction to remove the restriction enzyme (BsaI or BstZ17I) and T7 RNA polymerase.

### 2.3.2.2 Desalting of in vitro transcribed RNA

The phenol/chloroform treated transcription reaction was run through a 10-DG desalting column (BioRad Inc.) to remove the trace phenol/chloroform and significant amounts of DNA template and small molecule contaminants (including salt ions and NTPs). The 10-DG column was equilibrated with 20 ml RNA buffer (50 mM Tris-HCl, pH7.5, 100 mM NaCl). A 3-ml volume of phenol/chloroform treated transcription reaction was loaded onto the column and drained. The desired RNA transcript was eluted from the column by using 5 ml RNA Buffer. Columns were washed with the same buffer and reused until the entire large-scale transcription reaction had been desalted.

### 2.3.2.3 Purification of transcribed RNA using FPLC size exclusion chromatography

The desired RNA transcript fractions from the 10-DG column were further purified by FPLC size exclusion chromatography to remove the remaining DNA templates, abortive transcripts and NTPs. The FPLC system we employ is the ÄKTA Purifier 10 system with a Fac-950 fraction collector and a computer running the UNICORN 6 control software (GE Healthcare). The desalted RNA transcripts were
injected onto the size exclusion column via a 50-ml Superloop. Following injection, the RNA transcript was eluted from the column by RNA buffer at a constant rate of 2 ml/min, and the desired RNA fractions were collected (5 ml/fraction). The fractions containing the RNA of interest were confirmed by both denaturing and non-denaturing TBE-PAGE. Denaturing TBE-PAGE was performed as described earlier (Section 2.3.2.1). In the case of non-denaturing TBE-PAGE, electrophoresis was performed in 0.5 × TBE at 70 V, 4°C, and then the gel was stained by SybrGreen II (Invitrogen Inc.).

2.4 OAS1 activity assay

2.4.1 Overview

OAS enzyme activity has been monitored by several different methods. Traditionally, enzymatic activity of OAS enzymes was examined by direct detection of isotope-labeled 2’-5’-A using radioactive (³²P) ATP as reaction substrates (116). After incubation of OAS enzyme with dsRNA and ATP, the resultant 2’-5’-A are analyzed by thin-layer chromatography (TLC), PAGE, or high performance liquid chromatography (HPLC) to identify different forms of 2’-5’-A containing ³²P (117-121). Some effort has been made to develop nonradioactive methods to measure OAS activity. In this case, the detected product is inorganic pyrophosphate (PPI) generated during the production of 2’-5’-A by OAS enzymes. It has been reported that equal molar NADPH generated from PPI via an enzyme-coupled reaction has strong fluorescence, which can be measured spectrophotometrically (60, 122). The enzyme-coupled reaction involves three enzymes: UDP-Glc pyrophosphorylase, phosphoglucomutase and glucose-6-phosphate dehydrogenase (122). The drawback of this assay is the involvement of a multistep
enzyme reaction, which prolongs the protocol and increases its complexity. In this thesis, a more direct colorimetric assay has been employed to measure PPI generated by OAS1. PPI reacts with ammonium molybdate to form PPI-molybdate complexes in sulfuric acid. PPI-molybdate complexes develop a blue color in the presence of thio reagent (β-mercaptoethonal) and a developing reagent (Eikonogen) (123) (Fig. 11). The color change results in an absorbance maximum at 580 nm. This assay does not involve any additional enzymatic components and is sensitive up to 20 nmoles in a 1-ml reaction volume. Another advantage of this assay is the timesaving feature. It only takes 2 to 3 hours to finish the entire process as opposed to radioactive assay (usually one day).

**Figure 11  OAS activity assay outline**

PPI reacts with ammonium molybdate to form PPI-molybdate complexes in sulfuric acid. PPI-molybdate complexes develop a blue color in the presence of thio reagent (BME) and a developing reagent (Eikonogen) (123). The color change results on an absorbance maximum at 580 nm.
2.4.2 Procedures

A colorimetric method was developed to quantitate the amount of PP$_i$ product released upon the formation of 2’-5’-A by OAS1, modified from previously established assays (123, 124). OAS1 and RNA were incubated in the presence of 20 mM Tris-HCl, 5 mM MgCl$_2$, 1 mM DTT and 2 mM ATP in total volume of 100 µL at 37°C, and the reaction quenched at specific time points by the addition of 50 mM EDTA. A 100-µl aliquot of molybdate reagent (2.5% ammonium molybdate in 2.5 M H$_2$SO$_4$) and 100 µl of β-mercaptoethanol (BME) (0.5M) were added to the quenched reaction mixture to produce molybdophosphoric acid. To this mixture 40 µl of Eikonogen reagent (0.125 g of 1-amino-2-naphthol-4-sulfonic acid, 0.125 g of sodium sulfite, and 7.325 g of sodium bisulfite to 100 mL of ddH$_2$O) was immediately added and the final volume was adjusted to 1 ml with ddH$_2$O. The resulting molybdenum blue chromophore produced was then quantified by $A_{580nm}$ measurement, and compared to PP$_i$ standard solutions subjected to an identical process. Kinetic analysis used identical reaction conditions and followed a data analysis approach as outlined previously (60). Briefly, reaction velocities ($V$) were calculated by linear regression within the linear range of time course, ensuring that results were obtained in at least triplicate prior to analysis. The apparent dissociation constant ($K_{app}$) and the maximum reaction velocity ($V_{max}$) were determined using the following equation: $V = (V_{max} / 1 + K_{app} / [RNA])$ (Kaleidagraph, from Synergy Software) (60). Curves were fit using non-linear regression and the quality of the fit assessed by examination of the $R_{fit}$.
2.5 Electrophoretic mobility shift assays

OAS enzyme and VA1 RNA were incubated in binding buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl) at room temperature for 15 min. The reactions were mixed with native load mix (0.02% bromophenol blue, 0.01% xylene cyanol FF, 10% glycerol in 1×TBE), and loaded onto a native TBE-PAGE gel. Electrophoresis was performed at 70 V and 4°C. in 0.5×TBE for 3-4 hrs. To visualize RNA-containing species, gels were stained with SybrGreen II (Invitrogen Inc.) and imaged by FluorChem Q System (ProteinSimple, Inc.). Dissociation constant determination was performed according to the methodology outlined by Ryder et al (125). The fraction of bound RNA \( f \) is related to the dissociation constant \( K_d \) by the following equation: \( f = 1/1+(K_d/[P_t]) \), wherein \( P_t \) is the total protein concentration at equilibrium. By determining \( f \) values at multiple OAS1 concentrations, \( K_d \) at equilibrium was derived from a nonlinear least-squares fit (125). \( f \) values were determined by AlphaView® Q software (ProteinSimple).

2.6 Hydrodynamic radius determination

Dynamic light scattering profiles were measured using the Zetasizer Nano S system (Malvern Instruments Ltd., Malvern, UK). RNA and protein preparations were passed through a 0.1 μm filter (Millipore) before dilution and allowed to equilibrate to 20 °C prior to DLS measurements at the same temperature. Multiple dataset replicates were analyzed using the DTS software supplied by the manufacturer (version 5.10.2). The obtained diffusion coefficient (and calculated hydrodynamic radius) was corrected to standard solvent conditions.
2.7 Mass spectrometry analysis of protein-RNA complexes

Aliquots of pure protein or protein-RNA mixtures were pipetted into Slide-A-Lyzer units (Pierce) and dialyzed overnight against ammonium acetate buffer (99.999% Aldrich) (126). In some cases, some of the sample was removed, and the dialysis continued against a lower concentration of buffer. Actual buffer concentration ranged from 5 to 100 mM. Samples were diluted to approximately 1 μM, inserted into a New Objective PicoTip™, then analyzed on an electrospray time-of-flight instrument (127). The declustering voltage was varied in order to determine the relative stability of the complexes. Attempts to denature samples with acetic acid and methanol resulted in protein precipitation, and therefore we were unable to measure the protein in the unfolded state.

2.8 5’-end modification of RNA

Plasmid-based in vitro transcription of RNAs generates 5’-triphosphates (5’-PPP) under standard conditions. To generate a fully dephosphorylated 5’-ends (5’-OH), a 500-μl reaction containing purified RNA (50 μg) was treated with calf intestinal alkaline phosphatase (50U, New England Biolabs) in 1×NEBuffer3. To generate a 5’-monophosphate (5’-P), RNA (50 μg) was instead treated with RNA 5’ Pyrophosphohydrolase (50U, New England Biolabs) in 1×NEBuffer2. Reactions were incubated at 37 °C for 90 minutes, followed by repurification as described in section 2.3.2 using phenol/chloroform extraction, a 10-DG desalting column, and FPLC to
remove the modifying enzyme and reaction components. Confirmation that the RNA remained intact was confirmed by both denaturing and non-denaturing TBE-PAGE.
Chapter 3

Results

3.1 Introduction

Our main goal was to characterize the ability of VA\(_1\) RNA and its derivatives to regulate the activity of a key interferon-inducible member of the innate immune response, OAS1. A single study has demonstrated that full-length VA\(_1\) RNA activates the murine OAS enzyme, which is paradoxical given the inhibitory role that VA\(_1\) RNA plays with respect to PKR (42, 80). VA\(_1\) RNA binds to PKR and prevents the required self-association of PKR for activation (40). Recent investigations suggested that VA\(_1\) RNA is processed by Dicer into two species: a TS-lacking VA\(_1\) RNA and small RNA from TS \textit{in vivo} (84). Further, TS-lacking VA\(_1\) RNA that corresponds to the Dicer-processed version (VA\(_1\) \textit{ΔTS}) has been demonstrated to still serve as an inhibitor for PKR (128). In light of the discovery that Dicer efficiently truncates VA\(_1\), we decided to investigate the regulation of the specific OAS1 isoform (p42) by both the full-length VA\(_1\) and its truncated derivatives, including VA\(_1\) \textit{ΔTS}. Using a combination of biochemical approaches, we characterized both RNA-protein complex formation and activation/inhibition potential of these RNA molecules. Additionally, the importance of RNA 5’-end phosphorylation state to its ability to regulate OAS1 activity has been investigated. Detailed results will be discussed in the sections 3.2-3.6.
3.2 Expression and purification of active OAS1 from *E. coli*

Studies with purified OAS1 protein have been difficult because of yield and solubility problems, so we developed a new preparation method in which recombinant OAS1 is purified from *E. coli* as a fusion protein with highly soluble bacterial protein domains. Cleavage of the fusion tag results in a monomeric 42 kDa protein by denaturing SDS-PAGE (Fig.12a), and analysis of the trypsinized protein by MS confirmed OAS1 purification (data not shown). To test catalytic activity, a novel colorimetric assay was developed which correlates the detection of PPi with the production of 2’-5’-A chains. We prepared buffered reactions containing OAS1, ATP and MgCl₂ in the presence and absence of a known synthetic dsRNA activator (poly I:C), and 2’-5’-A synthesis was determined by detection of PPi production after incubation at 37 °C (Fig.12b). In the absence of activator, no detectable catalytic activity is observed, whereas in the presence of poly I:C, catalysis of 2’-5’-A chain formation is significantly enhanced at all time points examined, consistent with an active enzyme. To ensure that the activity of the purified recombinant OAS1 was consistent with previously reported values (60), kinetic experiments were performed in which increasing concentrations of activator (poly I:C) were incubated in the presence of OAS1, and PPi production determined at various time points. From the linear phase of these data, reaction velocities (*V*) were calculated, and plotted against poly I:C concentration in order to extract kinetic parameters (Fig.12c). The analysis was repeated at multiple OAS1 concentrations (50-400 nM), and determined an apparent dissociation constant (*K*<sub>app</sub>) of 17±3 μg/mL, and a maximum reaction velocity (*V*<sub>max</sub>) of 2.07±0.06 nmol/min. These results are consistent with previously reported values of *K*<sub>app</sub> (42 μg/mL) and *V*<sub>max</sub> (1.29 nmol/min) (60).
Figure 12  Purification of active recombinant human OAS1

(a) Denaturing SDS-PAGE analysis of OAS1 purification from *E. coli*. Lanes correspond to (left to right) molecular weight markers, lysate following sonication, the imidazole eluate from Ni-NTA affinity chromatography, cleavage of the fusion protein with TEV protease, and purified protein following size exclusion chromatography. The migration of fusion protein (GNSHT-OAS1), the cleaved affinity tag (GNSHT), and pure OAS1 protein are indicated. To be continued in next page.
(b) Purified OAS1 (300 nM) and polyI:C (20 μg/mL) were incubated in the presence of ATP (2mM) and MgCl₂ (5 mM) at 37°C and quenched at time points from 0-180 minutes to assay 2-5(A) chain formation. Errors represent the standard deviation from 3 replicates. (c) Enzymatic activity ($V_o$) is shown as a function of poly I:C concentration for OAS1 at 50 nM (I), 100 nM (▼), 200 nM (▲), 300 nM (u), and 400 nM (n) after 20 minute incubation. Higher concentrations were sampled, but the data was excluded as a result of poor fit as described in the Materials and Methods. Error bars reflect the error in the linear regression analysis in order to determine $V$. (d) Identical experiments as in (C) were performed, demonstrating the linearity of the assay with respect to enzyme concentration at low enzyme concentrations. Reaction velocity ($V$) is shown as a function of OAS1 concentration for poly I:C RNA at 0 μg/mL (x), 4.3 μg/mL (▼), 13.0 μg/mL (▲), 26.1 μg/mL (u), 43.5 μg/mL (n), and 65.2 μg/mL (l) after 20 minute incubation. Error bars reflect the error in the linear regression analysis in order to determine $V$.

Upon correcting for enzyme concentration used, a turnover number ($k_{cat}$) of $69 \pm 9$ min⁻¹ was determined for our preparation as compared to a value of 108 min⁻¹ reported previously. To ensure that enzymatic assays were being performed at appropriate OAS1 concentrations, the linearity of the assay was established by titrating different concentrations of protein at a fixed RNA concentration and time point (Fig.12d). For a given RNA concentration, the assay responds linearly to enzyme concentration at lower OAS1 concentrations, eventually resulting in saturation of activity when excess OAS1 is
added. As a result, we have confined activation assays to enzyme and RNA concentrations within the linear range in future experiments.

### 3.3 VA₁ lacking the terminal stem forms stable complexes with OAS1

To characterize the interaction between VA₁ RNA and OAS1, we produced four distinct RNA molecules to probe the regions responsible for interaction (Fig.5). In addition to full-length VA₁, the central stem alone (VA₁-CS), the apical stem alone (VA₁-AS), and a mimic of Dicer-processed VA₁ lacking the terminal stem (VA₁ΔTS) were examined. EMSA under non-denaturing conditions was used to probe the affinity of OAS1 for each RNA molecule. Under conditions of a 4-fold molar excess of RNA relative to protein, VA₁ΔTS was capable of the most significant complex formation with OAS1 (Fig.13a). VA₁-OAS1 and VA₁-CS-OAS1 complexes were also observed, whereas no detectable complex formation occurred with the apical stem alone at the concentrations examined. Quantitative comparison of binding affinities of full-length VA₁ and VA₁ΔTS for OAS1 was performed by full titration of RNA with increasing amounts of OAS1. VA₁ΔTS demonstrated the highest affinity, with conversion of the free RNA into two distinct higher molecular weight complexes (Fig.13b). An apparent dissociation constant ($K_D$) based on the quantitation of free RNA disappearance was determined to be 590±40 nM (Fig.13c). A 2.7-fold lower binding affinity (1610±80 nM) was determined when a similar analysis was performed with full-length VA₁.
Figure 13  VA₁ lacking the terminal stem forms stable complexes with OAS1

(a) EMSA for OAS1 (800 nM) binding to VA₁ RNAs (200 nM) under non-denaturing conditions. (b) EMSA for OAS1 binding to VA₁ΔTS (50 nM). Increasing amounts of OAS1 were added from 0-2 μM. (c) Quantitation of EMSA results for VA₁ΔTS (squares) and full length VA₁ (circles). Experiments were repeated in triplicate, with associated standard deviation indicated as error bars. Dissociation constant determination was performed according to the methodology outlined by Ryder et. al. (125).
Hydrodynamic radius ($R_H$) determination of (a) OAS1-VA$_1$ complex and individual components and (b) OAS1-VA$_1$ΔTS and individual components by DLS. OAS1 (8 μM) and RNA (2 μM) were mixed, purified, and equilibrated to 20 °C in the cuvette prior to acquisition. (c) Quantitation of DLS experiments as outlined in (a) and (b). Error bars represent the standard deviation from triplicate experiments.
To characterize the observed complexes, we subjected VA1-OAS1 and VA1ΔTS-OAS1 complexes to DLS analysis to determine complex size and polydispersity. Given that DLS requires significantly higher concentrations than EMSA approaches, this technique can also rule out the possibility that higher-order complexes were formed but not observed by EMSA. As comparison points, the hydrodynamic radii ($R_H$) of OAS1 (3.4±0.2 nm), VA1 (4.7±0.2 nm), and VA1ΔTS (4.1±0.1 nm) were determined (Fig.14). As expected, clear increases in $R_H$ to 5.3±0.1 nm and 4.6±0.1 nm are observed upon OAS1 complex formation with VA1 and VA1ΔTS respectively (Fig.14). Both VA1 and VA1ΔTS-containing complexes had less than 20% polydispersity, indicating a fairly uniform complex size.

3.4 Non-denaturing mass spectrometry of VA1ΔTS-OAS1 complex

EMSA results suggested that VA1 lacking the terminal stem forms two higher molecular weight complexes with OAS1. To determine the stoichiometry of these complexes, we characterized complexes using non-denaturing MS in positive mode. By manipulation of the buffer concentration, the relative concentrations of the two components, and the declustering voltage in the mass spectrometer, we were able to identify all components. OAS1 demonstrated the properties of a stable, well-folded, monomeric protein as only 4 charge states were observed (+11 to +14) (Fig.15a). Spectrum deconvolution identifies 4 major protein peaks starting at 42096 Da (calculated mass of 42100 Da) and each separated by 76 Da. Given that 76.01 Da corresponds to the mass of BME, the original reducing agent used in our OAS1 preparation, it was not
surprising that upon tryptic digest of the protein, the MALDI mass spectrum showed three pairs of ions separated by 76 Da. Tandem ms of these pairs identified three cysteines that had been covalently modified by BME which accounts for the multiple species in the deconvolution. The protein subsequently prepared using DTT as the reducing agent had one protein species of 42096 ± 5 Da and had no modifications (data not shown). Effects by BME covalent modification on complex formation was also demonstrated by EMSA results (Fig.16). When using BME for OAS1 purification, a single shifted complex was observed by EMSA (Fig.16a). When DTT was used instead of BME, two shifted complexes were observed by EMSA (Fig.16b). Analysis of the RNA component alone, VA1TS, proved problematic as it was not possible to run the sample in negative mode in the absence of OAS1. To circumvent this issue, we made a sample containing OAS1 with excess VA1TS and adjusted to descluterizing voltage such that only free RNA signal was detected. VA1TS shows a single ion envelope with four charge states (9+ to 12+) consistent with a well-folded nucleic acid molecule (Fig.15b).

To probe complex stoichiometry, the nanospray spectrum of OAS1-VA1TS complexes were generated from protein prepared with DTT as the reducing agent (Fig.15c). Given that the best spectra for OAS1 protein by itself were obtained with both high buffer concentration and high declustering voltage, while the best VA1TS spectra had the opposite requirements, a wide range of both parameters were tested in order to maximize the trade-off between resolution and maintenance of the non-covalent complex. Under the best compromise, four distinct charge envelopes were observed. The most prominent charge envelope (8+ to 11+ ions) exactly matches that observed for the free VA1TS shown in Figure 5B. More importantly, there are charge envelopes
corresponding to two distinct OAS1-VA₁ΔTS complexes; a prominent envelope (19+ to 25+) corresponding to a complex of 120356±166 Da and a subtle envelope (16+ to 18+) of a species with an average mass of approximately 78 kDa. Using the established molecular masses from OAS1 and VA₁ΔTS alone (Figs.15a and 15b), these measurements correspond to 2:1 and 1:1 OAS1:VA₁ΔTS complexes. A distinct charge envelope corresponding to free OAS1 (14+ to 16+) is present, but the higher charge states indicate partial unfolding (compare to Fig.15a). At 120 V declustering voltage, these ions were visible, and thus may represent a small amount of unfolded protein. As the voltage was increased, there was an increased abundance of the “unfolded protein” ions and the ions from the species of mass 78 kDa appeared, suggesting fragmentation of the 2:1 complex during the ionization/desolvation stage in the mass spectrometer.

When OAS1 protein is prepared in the presence of DTT, two OAS1-VA₁ΔTS complexes are clearly detected by both EMSA and non-denaturing ms, while only the 1:1 complex is found when the protein is prepared in the presence of BME (Fig.15d). The well-defined charge envelope near m/z 3500 (11+ to 13+ ions) are the same as those shown in Fig.15a for OAS1 alone. The clear ions shown from m/z 4500 to 6000 (13+ to 16+) represent a species that corresponds well with a 1:1 stoichiometry. This result is particularly interesting in light of the observation that EMSAs with OAS1 purified in the presence of BME only form a single higher molecular weight complex as opposed to the two observed for protein purified using DTT (Fig.15c). It is important to note that the relative intensities of the charge states is a product of both affinity and declustering voltage selection, and therefore does not necessarily reflect abundance in solution; however, the spectra shown in Figs. 15c and 15d were both generated with an
approximately equimolar mixture of protein and RNA, the major difference being the purification method used for the protein.

**Figure 15** Non-denaturing MS of OAS1:VA\textsubscript{1} TSA\textsubscript{21} complexes

(a) Nanospray spectrum of OAS1 prepared in buffer containing BME and buffer-exchanged into 100 mM ammonium acetate. Declustering voltage was 280 V. Deconvolution shown in the inset gives at least four major protein masses (units: Da), each of which has multiple adducts. The major peaks differ by about 76 Da, the mass expected for a 2-ME addition, and the minor ones are sodium.

*To be continued in next page.*
(b) Nanospray spectrum showing VA\textsubscript{I}\textgreek{TS} in 5 mM ammonium acetate with 150 V declustering voltage. Inset shows the deconvolution of the 9+ to 12+ ions.

(c) Section of a nanospray spectrum of a mixture of OAS1 and VA\textsubscript{I}\textgreek{TS} prepared in buffer (5 mM ammonium acetate) containing DTT. Declustering voltage was 180 V. There are two prominent charge envelopes labeled in bold type, the 8+ to 11+ ions that exactly match those of VA\textsubscript{I}\textgreek{TS}, and the 19+ to 25+ of a new species of mass 120356±166 Da (2:1 protein:RNA complex). Ions corresponding to OAS1 alone (14+ to 16+), and the 16+ to 18+ of a species of average mass 78291 Da are also indicated (1:1 protein:RNA complex). Non-denaturing EMSA of the mixture prior to ms analysis is inset. (d) Section of a nanospray spectrum of a mixture of VA\textsubscript{I}\textgreek{TS} and OAS1 prepared in buffer (50 mM ammonium acetate) containing BME. Declustering voltage was 250 V. The ions labeled 11+, 12+ and 13+ have the same \textit{m/z} values as the ions of the same charge state shown in (B) corresponding to OAS1. The clear ions from \textit{m/z} 4500 to 6000 are the 13+ to 16+ of a species mass 74772 ±184 Da. Non-denaturing EMSA of the mixture prior to ms analysis is inset.
Figure 16 Effects of reducing agents on OAS1:VA₁ΔTS complex formation

(a) EMSA for OAS1 (BME as reducing agent) to VA₁ΔTS (50 nM). Increasing amounts of OAS1 were added from 0-2 μM. (b) EMSA for OAS1 (DTT as reducing agent) to VA₁ΔTS (50 nM). Increasing amounts of OAS1 were added from 0-2 μM.
3.5 VA\textsubscript{I} lacking terminal stem is a poor activator of OAS1

Once we had firmly established the affinity and stoichiometry of complex formation, we sought to characterize the ability of VA\textsubscript{I} RNA to regulate the catalytic activity of OAS1. A novel colorimetric assay, which correlates the detection of pyrophosphate with the production of 2’-5’-A chains, greatly simplified this study. We prepared buffered reactions containing OAS1, ATP and MgCl\textsubscript{2} in the presence and absence of VA\textsubscript{I} RNA derivatives, and monitored pyrophosphate production after a 30-minute incubation at 37 °C (Fig.17a). In the absence of RNA or in the presence of an ssRNA control, basal levels of OAS1 activity were detected. A significant enhancement in OAS1 activity was observed in the presence of full-length VA\textsubscript{I} (6.3-fold) and VA\textsubscript{I}-AS (11.3-fold), the most potent activators observed. VA\textsubscript{I}-CS inclusion led to moderate OAS1 activation (3.3-fold). Surprisingly, VA\textsubscript{I} lacking the terminal stem was the least effective activator of OAS1, leading to nearly basal levels of activation. It should be noted that all RNAs demonstrated significantly lower stimulation of activity than poly I:C on a per mass basis (Fig.12b), although direct comparison to poly I:C is problematic due to its large size and heterogeneity (~90–1400 kDa). A more comprehensive time course under similar reaction conditions was performed to ensure that the results were not biased by the particular time point being examined (Fig.17b). At all time points measured, a similar trend was observed: VA\textsubscript{I}-AS was the most potent activator, followed by full-length VA\textsubscript{I}, the central stem derivative, and finally VA\textsubscript{I}\text{ATS} at levels approaching the negative control. Dose-response experiments in which OAS1-catayzed reaction velocities were determined under increasing RNA concentrations allowed estimation of the maximum reaction velocity ($V_{\text{max}}$) and apparent dissociation constant ($K_{\text{app}}$) (Fig.17c).
The results are summarized in Table 1, and support both the $K_D$ values as determined by EMSA (Fig.13c) and the trend outlined from a single time course (Fig.17b). A 2.0-fold increase in affinity and 4.7-fold decrease in $V_{\text{max}}$ were observed when comparing VA$_1$ATS to VA$_1$. Both $K_{\text{app}}$ values are consistent with those determined by EMSA. VA$_1$-AS achieves the highest maximum reaction velocity despite a significantly lower affinity than other RNAs tested ($K_{\text{app}} = 2.4$ μM). As expected, basal reaction velocities were observed when using an ssRNA control in the enzyme assay, although accurate parameter determination was not possible as a result of the high error associated with velocity estimations (reflected in the comparatively low $R_{\text{fit}}$ value). poly I:C achieved a maximal velocity comparable with the most potent activator examined (VA$_1$-AS) and a significantly higher affinity than any VA$_1$ derivative, although these values should be treated with caution as a direct comparison is clouded by the large size and heterogeneity of synthetic poly I:C.

To test our hypothesis that VA$_1$ATS was behaving as a pseudo-inhibitor, we established a competition experiment using a fixed concentration of the most potent activator, VA$_1$-AS, in the presence of increasing VA$_1$ATS (Fig.17d). As the concentration of VA$_1$ATS in the reaction mixture was increased, OAS1 activation was increasingly attenuated. Similar behavior was observed when using poly I:C as the activator, but quantitation of these results is again difficult due to the heterogeneity of poly I:C (data not shown). To ensure that these results were specific to VA$_1$ATS, we repeated the experiment replacing VA$_1$ATS with an ssRNA control. Under these conditions, no significant reduction in OAS1 activation was observed.
In all cases, errors represent the standard deviation from at least 3 replicates. (a) Purified OAS1 (300 nM) and VA₁ derivatives (300 nM) were incubated in the presence of ATP (2mM) and MgCl₂ (5 mM) at 37°C for 30 minutes, quenched, and 2-5(A) chain formation quantitated by PPᵢ detection. (b) OAS1 catalytic activity was determined as in (a), with the exception that the reactions were quenched at time points from 0-180 minutes. A control with no RNA was also performed, but was not shown graphically as it overlapped the ssRNA control.

To be continued in next page.
(c) Enzymatic activity is shown as a function of RNA concentration for OAS1 (300 nM). Error bars reflect the error in the linear regression analysis in order to determine OAS1 activity. (d) Pseudo-inhibition of OAS1 activation by VA$_{1}$TS. OAS1 (300 nM) catalytic activity was determined in the presence of VA$_{1}$-AS (300 nM) under increasing concentrations of VA$_{1}$TS (medium grey) or a ssRNA control (dark grey). The experiment was repeated with OAS1 (300 nM) in the presence of VA$_{1}$TS alone (light grey) to establish baseline. OAS1 activity was determined after a 30 minute incubation at 37 °C.

**Table 1**  
Estimated kinetic parameters for VA$_{1}$ derivatives and controls

<table>
<thead>
<tr>
<th></th>
<th>$K_{app}$ (nM)</th>
<th>$V_{max}$ (nmol/min)</th>
<th>$R_{fit}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>VA$_{1}$</td>
<td>1348 ± 130</td>
<td>0.66 ± 0.03</td>
<td>0.996</td>
</tr>
<tr>
<td>VA$_{1}$TS</td>
<td>663 ± 65</td>
<td>0.14 ± 0.02</td>
<td>0.995</td>
</tr>
<tr>
<td>VA$_{1}$-AS</td>
<td>2403 ± 187</td>
<td>2.1 ± 0.1</td>
<td>0.996</td>
</tr>
<tr>
<td>VA$_{1}$-CS</td>
<td>1746 ± 222</td>
<td>0.40 ± 0.03</td>
<td>0.997</td>
</tr>
<tr>
<td>ssRNA</td>
<td>160 ± 84</td>
<td>0.02 ± 0.01</td>
<td>0.643</td>
</tr>
<tr>
<td>Poly I:C</td>
<td>92 ± 6</td>
<td>1.97 ± 0.05</td>
<td>0.997</td>
</tr>
</tbody>
</table>

Data from Fig.17c was fit as outlined in the Materials & Methods section to determine $K_{app}$ and $V_{max}$ values. The quality of the fit is presented via the $R_{fit}$ value, with a value of 1 representing a perfect fit. Values for poly I:C are denoted (*) as the molecular weight of poly I:C is heterogeneous (these numbers reflect an estimate based on an average molecular weight of 200 kDa).
3.6 RNA dissociation is observed upon OAS1 activation

To test the importance of a transient RNA-protein association to the mechanism of OAS1 activation, EMSAs were performed on VA₁ΔTS RNA in the presence of OAS1 under activating (ATP/Mg²⁺) and non-activating (AMP/Mg²⁺) conditions (Fig.18a). RNA is shifted to higher molecular weight in the presence of OAS1 alone. Addition of ATP/Mg²⁺ or AMP/Mg²⁺ resulted in identical migration when compared to OAS1 alone. Upon incubation at temperatures sufficient for OAS1 activation (90 minutes), dissociation of the OAS1-VA₁ΔTS complex is observed when both ATP and Mg²⁺ are present. Quantitation of these results indicated a 4.2-fold reduction in RNA association with OAS1 upon activation (Fig.18b). Similar observations were made for VA₁-AS, however the low intensity of the EMSA results precluded quantitative evaluation. When AMP is employed in place of ATP, no RNA dissociation is observed. This result suggests that upon formation of the catalytically active OAS1 complex, OAS1 behaves in an RNA-independent manner.

3.7 Phosphorylation state at RNA 5’-end impacts OAS1 affinity and activation potential

It has been proposed that a mechanism whereby the host cell can discriminate foreign viral dsRNA from self is at least partially based on the modification present at the 5’-end. Furthermore, Dicer processing of VA₁ in vivo would typically result in a monophosphate group being left on the 5’-nucleotide of VA₁ΔTS. We sought to determine the impact, if any, the phosphorylation state of the 5’-end had on the ability of
VA\textsubscript{I}-derived RNAs to interact with and activate OAS1.

Figure 18  RNA affinity decreases upon even modest OAS1 activation

(a) Native gel mobility-shift for VA\textsubscript{I}ATS (300 nM) binding to OAS1 (300 nM) in reactions containing ATP (2 mM) or AMP (2 mM) and MgCl\textsubscript{2} (5 mM). Samples were incubated for the time indicated, resolved on 5% TBE gel, and visualized by SybrGreenII staining. (b) Quantitation of triplicate experiments from (a), with error represented as standard deviation.
*In vitro* transcription of RNA generates molecules with 5’-triphosphates (5’-PPP) due to the use of nucleotide-5’-triphosphates in the reaction mixture. We used commercially available enzymes to generate the 5’-monophosphate (5’-P) and 5’-hydroxyl (5’-OH) versions of VA₁ constructs and then repurified the RNAs to ensure that no residual enzyme or contaminants were present. Interestingly, alteration of VA₁ΔTS from a 5’-PPP to either a 5’-P or 5’-OH resulted in a greater than 60% decrease in activity (*Fig.19a*). A similar trend was observed for the most potent activator, VA₁-AS. To ensure that the treatment/purification of modified RNA did not contain residual enzymatic activity that could account for the data, identical assays were repeated with OAS1 omitted from the reaction mixture. Under these conditions, no significant change in PPi production was observed. OAS1 binding affinity to VA₁ΔTS was probed by EMSA and interestingly no significant decrease in affinity was observed when comparing the 5’-P to 5’-PPP derivative, although the 1:1 OAS1:RNA complex was not detected in the case of 5’-P (*Fig.19b*). A significant reduction in binding affinity was observed for the fully dephosphorylated RNA, indicating the potential importance of charge at the 5’-end.

### 3.8 Summary

By employing a combination of biochemical approaches, both VA₁ RNA-OAS1 complex formation and OAS1 activation/inhibition potential of these RNA molecules have been investigated. Additionally, the importance of RNA 5’-end phosphorylation state to its ability to regulate OAS1 activity has also been investigated. Our results demonstrated that VA₁ΔTS, the most physiologically relevant VA₁ RNA derivative, serves as a pseudo-inhibitor for OAS1 enzyme.
Figure 19  
5’-end phosphorylation impacts activity and affinity for OAS

(a) Transcribed VA1-AS and VA1ΔTS containing 5’-triphosphates (5’-PPP) were enzymatically modified to form either 5’-monophosphate (5’-P) or completely dephosphorylated 5’-end (5’-OH) prior to purification by size exclusion chromatography. Purified OAS1 (300 nM) and RNA (300 nM) were incubated in the presence of ATP (2mM) and MgCl₂ (5 mM) at 37°C, quenched, and 2-5(A) chain formation quantitated by PPᵢ detection. As a control, reactions were repeated with OAS1 omitted. In all cases, errors represent the standard deviation from 3 replicates. (b) EMSA for OAS1 binding to VA1ΔTS (100 nM) with various 5’-end phosphorylation states. Increasing amounts of OAS1 were added from 0-2 μM and shifted complexes detected on 5% non-denaturing gels.
Chapter 4

Discussion and Conclusions

4.1 Discussion

VA1 RNA is transcribed in the late stages of infection at high concentration (~μM range) and has been demonstrated to attenuate the activity of a number of key players in the innate immune response including PKR (through competitive inhibition) and the RNA silencing machinery (through processing and incorporating the terminal stem of VA1 into the silencing machinery via the activity of Dicer) (84, 128). Interestingly, a previous report has demonstrated that, in vitro, VA1 has the opposite effect on OAS1, an interferon-induced member of the innate immune response (42). We hypothesized that this seemingly contradictory observation could be resolved by investigating VA1 RNA lacking the terminal stem as this would be generated by the RNA silencing machinery. We initiated investigations into a specific OAS1 isoform and examined binding affinity, complex stoichiometry, activation potential, and role of RNA 5’-end modifications in the process. Overall, we can conclude that while full length VA1 is an activator of OAS1 in vitro, VA1ΔTS is a poor activator (or pseudo-inhibitor), consistent with its role in inhibiting PKR (128). Therefore, Dicer-processed VA1 could potentially serve to downregulate both RNAi and dsRNA responses to viral RNA.

In order to investigate the ability of VA1 RNA to regulate OAS1 activity, it was necessary to develop an efficient OAS1 expression and purification system. In this thesis,
an *E. coli* protein expression system has been developed and optimized for the specific OAS1 p42 isoform. Since OAS1 p42 is the smallest and simplest of human OAS enzymes, we decided to start with this specific isoform. In order to overcome traditional yield and solubility issues, a fusion protein including highly soluble bacterial protein domains, GB1 and NusA, were added to OAS1 (Fig.6). The presence of a TEV protease site enables the removal of the fusion tag to generate a monomeric OAS protein confirmed by denaturing SDS-PAGE, non-denaturing MS, and SEC (Figs.12a, 15a and 9). Catalytic activity of purified OAS1 was examined by incubating in the presence and absence of a potent synthetic dsRNA activator (poly I:C). The results are consistent with an active enzyme (Fig.12b). Due to the additional required step to cleave the GNSHT tag from target protein, the final yield of OAS1 enzyme is 1.5 to 2.0 mg (0.036 to 0.048 μmol) per 1L cell culture, which is sufficient for most biochemical analysis. For protein structural analysis, especially nuclear magnetic resonance (NMR) and x-ray crystallography, the volume of cell culture needs to be scaled up. In term of cost, conventional medium (LB medium) is used and TEV protease is prepared in-house, which makes the cost of this purification procedure significantly lower than the established insect cell system. With regard to time, it takes four days to produce the pure OAS1 protein, including expression, induction and purification procedures. Furthermore, this system can be directly applied to the purification of OAS1 mutants. Establishing OAS expression/purification system represented the majority of the work of this project, but will now be useful for the purification of mutants of different OAS isoforms.

We produced four distinct VA₁ RNA molecules to study their potential for activation/inhibition of OAS1. Each RNA was *in vitro* transcribed and purified
extensively following an established purification procedure. Pure RNA species can now be generated in one week at a high yield for biochemical and structural studies. While full-length VA₅ serves as an activator of OAS1, a terminal stem deleted version of the RNA (VA₅ΔTS) serves as a poor activator of OAS1 relative to other RNAs examined (Figs.17b and c). In fact, competition studies with a potent OAS1 activator indicate pseudo-inhibitor behaviour of VA₅ΔTS (Fig.17d). We do not believe that contaminants from in vitro transcription or degradation products could be responsible for this behaviour as RNAs are purified by size exclusion chromatography and their homogeneity confirmed by gel electrophoresis. Furthermore, a known ssRNA molecule produced in an identical manner neither activates nor inhibits OAS1 activity. These results are consistent with those observed for PKR, wherein VA₅ΔTS is an effective PKR inhibitor (128). Removal of the central stem from VA₅ΔTS results in the formation of a potent OAS1 activator, indicating the central stem prevents OAS1 activation. The role of the central stem still needs to be parsed out, but a plausible hypothesis is that, in a manner similar to that observed for PKR, the central stem sterically precludes OAS1 self-association (40, 81). These results are consistent with a study that has shown that the apical and terminal stems are the key contributors to the activation of OAS1 by full length VA₅ RNA (42).

A colorimetric method was developed and employed to examine the OAS1 catalytic activity by detecting P Pi generated from the OAS1 enzyme reaction. The amount of P Pi indicates the formation of 2’-5’-A chain which reflects the OAS1 reaction rates. This assay does not involve any additional enzymatic reaction or any radioactive reagent, and is sensitive up to 20 nmoles in a 1 ml reaction volume. Another advantage
of this assay is the timesaving feature, as it takes only 2 to 3 hours to finish the whole experiment. When using the potent synthetic dsRNA activator (poly I:C), the detected OAS1 activation level is comparable with other published results (42, 44). Since the formation of 2’-5’-A chain is not measured directly, another method (e.g., radioactive assay) is recommended to validate this assay. We have attempted to employ HPLC (C_{18} reverse phase column) to directly identify 2’-5’-A molecules. Preliminary results (data not shown) demonstrated that after OAS1 reaction the amount of substrate ATP decreased significantly compared with OAS1-free control. We could not identify the 2’-5’-A peak from HPLC spectra since we do not currently have 2’-5’-A standards in hand. Comparison to the radioactive assay, HPLC detection of 2’-5’-A chain formation is another logical step.

The literature presents conflicting reports about the oligomerization state of OAS1 upon activation by dsRNA. While some reports claim that OAS1 tetramerization is required (56, 129), crosslinking experiments have indicated that both the latent and activated form of the enzyme are monomeric (58). While our data do not resolve this conflict, we do not observe tetramer under any conditions examined with VA_{l} RNA. We focused our attention on the OAS1-VA_{l}ΔTS interaction, as stable complexes could be analyzed. VA_{l}ΔTS, forms two distinct complexes as detected by EMSA, and characterization of these complexes by non-denaturing MS identifies these complexes as 1:1 and 2:1 OAS1:VA_{l}ΔTS (Fig.15c). To our knowledge, this is the first non-covalent RNA:protein interaction characterized using this methodology. This method has, however, been used successfully in the characterization of DNA-protein complexes (130, 131). DLS results, which are performed at significantly higher concentrations than
EMSA, indicate that the formation of a monodisperse complex that most likely represents the 2:1 OAS1:RNA complex alone. These results may suggest two independent OAS1 binding sites on the dsRNA molecule, although our data cannot exclude the possibility that OAS1 self-association upon RNA binding is responsible for the interaction.

In our initial protein preparations, OAS1 was purified in the presence of BME (instead of DTT) as a reducing agent, which we later determined by MS covalently modified the OAS1 protein. Interestingly, in this case a single shifted complex was observed by EMSA (Fig.16a) and it corresponded to the 1:1 complex of OAS1:VA₁ΔTS (Fig.15d). When DTT was used instead of BME, two shifted complexes were observed by EMSA (Fig.16b) and it corresponded to the 1:1 and 2:1 complexes of OAS1:VA₁ΔTS (Fig.15c). Therefore, it appears likely that the covalent modification of OAS1 with BME serves to disrupt an important interaction, and we recommend abandoning its use in the examination of OAS1 enzymes.

A previous study of the activation of oligoadenlyate synthetases by double-stranded RNA aptamers demonstrated that a given RNA activator could be fit to a kinetic model where the apparent dissociation constant ($K_{\text{app}}$) and the maximal reaction velocity ($V_{\text{max}}$) were demonstrated to behave as independent variables (60). The VA₁ RNA molecules used in this study showed similar behaviour when fit to the kinetic model (Table 1). Comparison of VA₁ to VA₁ΔTS, the most biologically relevant example, reveals that while VA₁ΔTS has a significantly reduced $V_{\text{max}}$, it has a greater affinity for OAS1 than the full-length VA₁. This would be beneficial in terms of inhibition as the processed version of VA₁ could outcompete RNA activators with lower affinities.
Therefore flooding host cell with VA₁ RNA represents an effective mechanism to suppress the OAS1-mediated innate immune response. These results reinforce the importance of understanding both the binding affinity and activation potential for potential binding partners of OAS enzymes, as consideration of each parameter independently can lead to misinterpretation.

The mechanism of OAS1 activation is thought to proceed through a two-step process (60). First, dsRNA binds to the OAS enzyme in a relatively non-specific way followed by a conformation change to OAS enzyme structure. However the fate of the RNA throughout the activation process remains a key piece of information not fully understood. When incubated for 90 minutes sufficient for OAS1 activation, dissociation of the OAS1-VA₁ΔTS complex is observed under activating conditions (both ATP and Mg²⁺ present) (Fig.18a). This observation indicates that dsRNA does not remain associated with OAS1 under conditions that lead to catalytic competence. This hypothesis is supported by previous observations for PKR, wherein the dsRNA release was observed after autophosphorylation of PKR (132).

One of the suggested mechanisms whereby the innate immune system differentiates foreign from host dsRNA is via the modification of 5’-end phosphorylation state (89). VA₁ RNA is transcribed as an unmodified, non-polyadenylated transcript that accumulates in the cytoplasm at late times of infection (74). We have highlighted the importance of the nature of the 5’-end of VA₁ RNA to the catalytic activation of the enzyme. VA₁ΔTS wherein the 5’-end possessed either (i) the in vitro modification, a 5’-triphosphate (5’-PPP), (ii) the typical in vivo modification after processing a monophosphate (5’-P), or (iii) a 5’-end devoid of phosphates (5’-OH) revealed that the
5'-P and 5’-OH demonstrated a significantly reduced ability to stimulate 2’-5’-A formation via OAS1 (Fig.19a). Affinity of VA₁ΔTS RNA for OAS1 is similar whether a 5’-PPP or 5’-P is present, however the RNA construct lacking 5’-phosphates (5’-OH) had a significantly reduced affinity for OAS1 (Fig.19b). These data suggest an inhibitory mechanism whereby Dicer cleavage of VA₁ to VA₁ΔTS generates an RNA molecule that maximizes its ability to interact with and suppress OAS1 activity. Preliminary examination of VA₁-AS indicates that the phosphorylation state present at the 5’-end of RNA may represent a more general phenomenon in the activation of OAS1, and will require an extensive examination of a variety of dsRNA molecules to confirm. However, these initial results are supported by the observation that the presence of an intact 5’-triphosphate is necessary for the innate immune responses mediated by other dsRNA responders, including RIG-I and PKR (89).

4.2 Conclusions

This thesis set out to characterize the particular regions of VA₁ RNA that contribute to the activation of OAS, to determine the regulatory effect of VA₁ RNA on OAS activity, and to identify the structural characteristics of OAS-VA₁ RNA complex. Using a combination of biochemical approaches, both VA₁ RNA-protein complex formation and OAS1 activation/inhibition potential of these RNA molecules have been characterized. Additionally, the importance of RNA 5’-end phosphorylation state to its regulatory ability for OAS1 activity has been investigated. This study confirms previous findings that VA₁ RNA can activate OAS1 enzyme and contributes additional evidence
that suggests that physiologically important Dicer-processed VA₁ lacking the terminal stem acts as a pseudo-inhibitor of OAS1.

**Figure 20** VA₁ simultaneously antagonize both the RNAi machinery and the IFN-inducible antiviral proteins

The Dicer-processed version of VA₁ RNA lacking terminal stem inhibits the activation of both PKR and OAS enzymes to enable protein synthesis required for virus replication. Also, the terminal stem is incorporated into the RNAi machinery to suppress RNA interference.

The findings from this thesis suggest a model (Fig.20) illustrating interaction mechanism between VA₁ RNA and its protein partners of the innate immune response. The Dicer-processed version of VA₁ RNA lacking terminal stem inhibits the activation of
both PKR and OAS enzymes, two key IFN-inducible antiviral proteins, to enable the protein synthesis required for virus replication in virus-infected cells. VA₁ RNA also binds Dicer via its terminal stem to competitively block Dicer enzyme to eventually suppress RNAi responses to viral infection. Taken together, the current data suggests a plausible strategy whereby adenoviruses use a single VA₁ RNA transcript to simultaneously antagonize both the RNAi machinery (via a processed terminal stem) and the interferon response (via the remaining apical and central stems).

4.3 Future studies

Since the current thesis only focuses on the regulation of OAS1 enzymes, it is recommended that further investigations be undertaken by using the experimental approaches of this thesis in the following areas:

(i) Further examination of different OAS variants, particularly OAS2/OAS3 isoforms is required to understand the molecular basis for their regulation by viral dsRNAs. The *E. coli* expression and purification procedure established in this thesis can be used for structural studies of other OAS variants, particularly OAS2/OAS3. However, it is critical to express these proteins in human cells for cellular and functional investigations because post-translational modifications are thought to be required for these isoforms. I made attempts to express OAS1 enzyme in HEK293T cell, but results from the trial experiments were not successful at the molecular cloning stage (data not shown).

(ii) This thesis was unsuccessful at resolving the conflict about the oligomerization state of OAS1 upon binding by dsRNA. By EMSA and non-denaturing
MS, 2:1 OAS1:VA1ΔTS have been observed, however, no OAS1:VA1ΔTS complex has been purified by size exclusion chromatography. Crosslinking of OAS1 with its RNA cofactors by UV radiation or chemical coupling agents could be a solution to solve these problems. Since VA1ΔTS behaves as a pseudo-inhibitor for OAS1 in vitro, it cannot be ruled out that VA1ΔTS prevents OAS1 enzyme from forming tetramer. Thus, it is necessary to investigate OAS1 oligomerization state upon binding by a potent RNA activator by employing the same experimental methodologies as used for VA1ΔTS.

(iii) Further investigation using the same experimental set-up is recommended for other viral dsRNA, particularly EBER1 RNA, since it has similar secondary structure and inhibitory effects on PKR as VA1 RNA. It would be interesting to determine the regulatory effect of EBER1 RNA version lacking the TS stem on both PKR and OAS enzymes for comparison.

(iv) Preliminary examination of the 5’-end phosphorylation state of RNA indicates that 5’-end modification is important to the catalytic activation of OAS1 enzymes. We compared the OAS1 binding affinity and activation potential of VA1 RNA with three different 5’-ends (5’-PPP, 5’-P, and 5’-OH). Further investigation is recommended to examine the effect of 7-methylguanosine capped RNA on OAS1 activation. Also, a detailed kinetic analysis should be performed on 5’-end modified RNAs.

(v) The current thesis was unable to initiate high-resolution structural studies (particularly, NMR and x-ray crystallography) for OAS1-dsRNA complexes. Future
studies should therefore concentrate on resolving high-resolution structures of OAS enzymes and OAS-dsRNA complexes.
References


67. Rebouillat D, Hovnanian A, Marie I, Hovanessian AG. The 100-kDa 2',5'-oligoadenylate synthetase catalyzing preferentially the synthesis of dimeric pppA2'p5'A


